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Peer recovery specialists play a key role in addressing the current opioid crisis. 
The Opioid Survivor Outreach Program (OSOP) peer recovery specialist intervention 
was designed to support opioid overdose survivors. In this program, patients are 
connected with a peer recovery specialist and are provided connection to treatment, 
support services, and harm reduction tools. This study was a quasi-experimental, 
mixed-methods approach to evaluate the impact of OSOP on opioid-related and all-
cause hospital visits and acute care cost avoidance. Chapter 1 focuses in on evaluating 
impact of OSOP on hospital visits while Chapter 2 evaluates the impact on cost 
avoidance through the assessment of hospital charges. The third chapter leverages in-
depth interviews from OSOP peer recovery specialists, nurses, and physicians to allow 
for a more comprehensive understanding of the program’s efficacy. Narrative content 
analysis was used to analyze the interview data from 11 participants. 
A historical control group was selected through propensity score matching to 
compare hospital visit and charges data with a study population at four study setting 
hospitals. A negative binomial regression was used to assess the differences in hospital 
visits among the groups while two sample t-test was used to analyze differences in 
hospital charges. OSOP was found to reduce expected opioid-related visits by 32.5% in 
the pre and post-enrollment OSOP study group, as well as all-cause hospital visits. 
Opioid-related hospital visits result in $703 more in charges when compared to non-
opioid related visits. When analyzing gross charges and programmatic costs, the OSOP 
program allows the healthcare system to avoid $1.1M in opioid-related hospital charges 




OSOP program is an intervention that assists patients in seeking substance use and 
supportive services while reducing acute hospital utilization and cost. Interviews from 
participants confirmed that a peer recovery specialist lived experiences encourage 
patients to enroll in OSOP. Peers have a command of the treatment ecosystem to 
effectively advocate and link patients to care. Further, insights from providers give other 
health institutions considerations on how to build a successful OSOP program in the 
emergency department environment.  
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avowed that none of his children or grandchildren would have a career in the dark 
underground. Possessing only a grade school education, he believed that going to 
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 The opioid epidemic has had a profound impact on residents in the United 
States. Its impact has left peril in nearly every corner of the country, including a rapid 
increase in opioid-related deaths over the past decade. Families experience the peril of 
the epidemic in different ways. Babies are born with neonatal abstinence syndrome, and 
grandparents are often forced to raise their grandchildren due to the death of parents 
from opioid misuse. In Maryland alone, nearly 2,000 residents have died from opioid-
related events in each of the last few years (“National Institute on Drug Abuse,” 2019). 
In response, state and federal agencies have stepped in to address the crisis through 
the declaration of emergencies and new sources of funding. The 21st Century Cures Act 
of 2016 passed by Congress provided states with funds to develop initiatives to curb 
deaths. One of the promising interventions to curb the epidemic is to deploy peer 
recovery specialists to the frontline in hospital settings.  
 Peer recovery specialists, who play an increasingly prominent role within the 
behavioral health medicine field, have lived experience with mental health issues or 
substance use in their past. Their role is to work with patients or clients to assist in their 
care and recovery journey. Leveraging the role of peer recovery specialists, this 
research study seeks to evaluate the implementation of an initiative in Maryland to 
respond to the opioid epidemic using funds from the federal 21st Century Cures Act of 
2016. The Opioid Survivor Outreach Program (OSOP) launched at four regional 
hospitals in the Baltimore area integrates a peer recovery specialist in emergency 
departments. The peer’s role is specifically to work with individuals who have 




developing rapport, and eventually connecting them to treatment as part of the 
program’s long-term success metrics. 
 With these interventions and supports provided through OSOP, this research 
hypothesizes a potential impact on reducing future opioid-related hospital visits, and 
therefore, provides for the hospital or healthcare system to avoid healthcare costs. This 
research seeks to inform whether interventions such as peer support are not only 
valuable to improve patient outcomes, but also are beneficial as it relates to healthcare 
system financial incentives and value-based payment models. This research leverages 
a mixed-methods approach of quantitative and qualitative data to guide and frame 
future practice and policy implications of the program’s impact. This dissertation thesis 
is compiled in four separate chapters. The purpose of the research is to bring new 
evidence to the field of public health on a current, relevant public health crisis. The 
following components, facilitated through a three-part manuscript, are outlined below. 
▪ Chapter 1: Engaging Opioid Overdose Survivors: Impact of Peer Recovery 
Specialists on Patient Utilization: This chapter explores whether engagement 
with an OSOP peer recovery specialists reduces emergency department, 
observation and inpatient admissions specific to opioid-related and all-cause 
visits. The analysis includes a retrospective review of data comparing a group of 
patients that received the intervention versus a historical control group that did 
not receive the intervention.  
▪ Chapter 2: Engaging Opioid Overdose Survivors: Impact of Peer Recovery 
Specialists on Health System Cost Avoidance: This chapter builds on patient 




explores whether engagement with an OSOP peer recovery specialist results in 
health system cost avoidance by preventing unnecessary utilization. The analysis 
uses real charges from hospital visits to estimate the financial value and impact 
of the program’s implementation.  
▪ Chapter 3: Engaging Opioid Overdose Survivors: Insights from the Field on 
the Role and Efficacy of Peer Recovery Specialists: This chapter involves 
adding qualitative data through in-depth interviews with frontline personnel 
engaged with the targeted patient population within the study hospitals. It 
involves interviewing OSOP peers, as well as physician and nurses to provide a 
more comprehensive understanding of three areas – effective strategies used to 
engage patients in OSOP, best practices in linking and referring patients to care, 
and assessing the integration of the OSOP peer as a member of the 
multidisciplinary healthcare team. 
▪ Policy Memorandum: Practice and Policy Considerations from Research: 
This thesis includes a separate analysis to bring findings from each of the three 
manuscripts together to provide public health practice and policy implications of 
this research. The items outlined translate the favorable research results – 
reduction in hospital visits by engaging in OSOP and significant, compelling 
healthcare costs avoided by hospitals and healthcare system – into concrete 
recommendations for changes in the public and behavioral health medicine 
science field. There are four specific opportunities detailed in this section:  
Practice Implications:  




▪ Expansion of Peer Recovery Specialists in Alignment with Value-Based 
Payment Models 
Policy Implications: 
▪ Provides Evidence for Reimbursement of Peers in Maryland and Broader 
Reimbursement Strategies for Commercial Payors 




















Chapter 1: Engaging Opioid Overdose Survivors: Impact of Peer Recovery 
Specialists on Patient Utilization  
Abstract 
Objectives: To evaluate the effectiveness of Opioid Survivor Outreach Program 
(OSOP) peer recovery specialist intervention on opioid-related and all-cause hospital 
visits.  
Design: Program evaluation with a study and historical control group using propensity 
score matching. Negative binomial regression was performed to assess the differences 
in hospital visits among the two groups. 
Setting: Four hospitals in urban and suburban areas of Baltimore, Maryland metro 
region. 
Participants: There were 416 in the study group that received the OSOP intervention. 
Individuals are identified primarily in the emergency department and are known opioid 
overdose survivors. A historical control group of 416 individuals was used to compare 
results. 
Intervention: OSOP provides peer recovery specialist services to patients, including 
opioid education, harm reduction tools, and refers and/or links patients to substance use 
treatment and recovery support services. 
Main Outcome Measure: Analysis of opioid-related and all-cause hospital visits.  
Results: As an intervention, OSOP helps to reduce expected opioid-related visits at a 
statistically significant level. There is a 32.5% reduction in expected opioid-related visits 
pre and post-enrollment into OSOP among the study group. There were also observed 




groups. OSOP also proved effective in finding observed reductions in expected all-
cause hospital visits. 
Conclusions: The findings suggest that the OSOP program is an intervention that 























Introduction and Statement of the Problem 
 Opioid-related deaths in Maryland have been increasing since 2010. According 
to the Centers for Disease Control (CDC), Maryland experienced 504 opioid-related 
deaths in 2010 compared to 2,087 deaths in 2018 (“National Institute on Drug Abuse,” 
2019). The increase in deaths has garnered attention at both the state and national 
levels. In March 2017, Republican Governor Larry Hogan declared the epidemic a state 
of emergency (“Governor Larry Hogan - Official Website,” 2018). Central to the 
response to the epidemic in partnership with emergency medical service responders, 
local communities, and policy departments are hospitals. Hospitals serve as a front door 
to treating individuals experiencing substance use disorders, as well as opioid overdose 
events.  
In 2013, a review of all opioid-related deaths in the state of Maryland showed that 
66% had at least one emergency department visit before their death and 59% had an 
opioid-related visit based on coding data sources (Holler, 2016).  In fact, 14% of those 
patients had 4 or more visits that were opioid-related in the 12 months before their 
death (Holler, 2016). In 2014-2015, 140,000 patients with a hospital emergency visits 
related to substance use were six times more likely to experience a fatal overdose 
compared to patients presenting with non-opioid-related concerns (Krawczyk et. al., 
2020). More recent studies in other states also report similar fatality trends. In a review 
of nearly 12,000 patients treated for opioid-related events in emergency departments 
across Massachusetts in 2015-2016, 5.5% of patients (1 in 20) died within 1 year of 





In Maryland, hospitals across the state began to implement evidence-based 
protocols such as Screening, Brief Intervention, and Referral to Treatment (SBIRT – 
Appendix: Figure 1), a universal substance use screening tool. Through July 2014 and 
November 2018, more than 1 million patients have been screened and 17.2% of 
patients reported alcohol or substance use over the previous year (Monico, et. al, 2020). 
As a front door to communities and people experiencing substance use disorders, 
hospitals have become an increasingly important stakeholder to leverage SBIRT to 
identify, address, and refer patients to substance use treatment using peer recovery 
specialists (Hargraves et al., 2017). Peer recovery specialists are being adopted rapidly 
by hospitals and health systems across the country, largely in response to federal and 
state recognition that such services could potentially be a critical component of saving 
lives. Initial studies have examined the impact of these programs as it relates to the 
number of patients connected to peers, such as studies in Rhode Island. Deployment of 
peers in hospital settings resulted in 1,208 people being served by peers with almost 
half receiving substance use treatment (Waye et al., 2019). This research seeks to go 
beyond an evaluation of process metrics related to these programs and determine its 
impact on subsequent hospital utilization after being connected with a peer recovery 
specialist specific to targeting opioid overdose survivor patients.  
At all four MedStar hospitals in the Baltimore region, funds to implement OSOP 
peer recovery specialist positions were provided through state grants as apportioned by 
the 21st Century Cures Act of 2016. Metrics from all four hospitals are collected and 
reported as they relate to how many patients engage with the OSOP peer recovery 




Nonetheless, metrics related to the value-based payment model in the state of Maryland 
known as Total Cost of Care, an effort to reduce the total cost of care by reducing 
emergency, observation, and inpatient hospital expenditures, have not been evaluated 
(“Maryland’s Total Cost of Care Model,” 2017).  
Informed in partnership with the Maryland Department of Health and the Mosaic 
Group, a community health services national consulting firm, a detailed workflow and 
description of the intervention and navigation process conducted by the opioid survivor 
outreach specialist is detailed in Figure 1 below (Holler, 2016). The OSOP peer 
recovery specialist conducts a multi-pronged effort as part of the intervention, which on 
average is a 30-90-day engagement period with each enrolled patient. Without the 
OSOP peer recovery specialist as an integrated member of the healthcare team, those 
experiencing an opioid overdose event would not receive any of the navigation services 






























Implementation at MedStar Health was first launched in the Baltimore regional 
hospitals in March 2018. The hospitals included MedStar Harbor Hospital, MedStar 
Good Samaritan Hospital, MedStar Union Memorial Hospital and MedStar Franklin 
Square Medical Center. MedStar Harbor Hospital and MedStar Franklin Square Medical 
Center employ one OSOP peer recovery specialist each for their respective campuses. 
Given the overlapping service areas, MedStar Union Memorial Hospital and MedStar 
Good Samaritan Hospital share an OSOP peer recovery specialist between their two 
Patient Arrival to 
Emergency Department 
RN Triage / Administer 
SBIRT Screen (18+ years 
or older) 
Patient Suspected of Opioid 
Overdose as Reason for Visit 
OR 
Patient self-reports opioid use as 
part of SBIRT Screen 
OR 
OSOP peer specialist receives 
referral from member of clinical 
care team 
OSOP Navigation – In ED 
1. Introduction and overview of 
OSOP program 
2. Determine level of interest in 
treatment/assistance 
3. Make referrals to 
outpatient/inpatient treatment 
providers and/or support 
services (housing, food, etc.) 
4. Educate patient on opioid use 
and risk 
5. Provide patient with 
naloxone kits 
6. Receive correct contact 
information for follow up post-
discharge 
7. Document all interactions in 
electronic medical record 
Post-Discharge from ED/Hospital 
1. Conduct home visit and/or connect 
with patient in public setting 
2. Develop rapport with patient 
3. Continue to make referrals to 
treatment and support service services 
4. Attend follow up appointments with 
patient 
5. Advocate for patient through 
healthcare delivery system 






campuses. Therefore, three OSOP peer recovery specialists cover all four hospitals. 
Through the period of March 2018 – July 2019, the OSOP peer recovery specialists 
have worked with 615 patients. Table 1 lists the process metrics that have traditionally 
been tracked to measure the success of the program. 
Table 1: Opioid Survivor Outreach Program Process Metrics from March 2018 – 
July 2019 at MedStar Health  
Metric # of Patients 
Patients Successfully Engaged 
with OSOP Peer Recovery 
Specialists 
615 
Patients Referred to Recovery 
Support Services 
286 or 47% 
Patients Referred to Treatment 188 or 31% 
Patients Confirmed to be Linked 
to Treatment  
142 or 23% 
 
**Note: Patients may fall within multiple categories; therefore, may add up to more than 100% 
The current study aims to evaluate whether the OSOP program reduces avoidable, 
unnecessary hospital utilization, which in turn would align with the health care policy 
goals of the state. Specifically, this study seeks to answer the following research 
questions: 
1. Did patients receiving the OSOP peer recovery specialist intervention (study 
group) experience a reduction in opioid-related and all-cause hospital visits pre 
and post-enrollment in the program over a 12-month period? 
2. Did patients that received the OSOP peer recovery specialist intervention (study 
group) when compared to a historical control group of patients experience a 






Defining Peer Recovery Specialist Services, History, and Significance  
Individuals offering peer support without formal clinical training as an integral 
member of the healthcare delivery system have manifested in a variety of forms. One 
type of community health worker that has emerged as providing specific peer support 
often focused on a specific disease state or specific disease state(s) is known as a peer 
recovery specialist. Other names for this role include peer recovery coach, mentor, and 
advocate (Davidson, Chinman, Sells, and Rowe, 2005). Peer recovery specialists have 
been instrumental in assisting individuals with substance use and mental illness. The 
United States Substance Abuse and Mental Health Services Administration (SAMHSA) 
defines these peer providers as “a person who uses his or her lived experience of 
recovery from mental illness and/or addiction, plus skills learned in formal training, to 
deliver services in behavioral health settings to promote mind-body recovery and 
resilience (“Peer Providers,” n.d.). Peer recovery specialists have gained traction as 
advocacy, self-help organizations, and twelve-step-based programs began to rise with 
more prominence (Myrick and Vecchio, 2016). One of the first programs, Alcohol 
Anonymous, began in the late 1930s. Throughout the past century, other similar groups 
have been created that model the organization’s approach, including Narcotics 
Anonymous and Al-Anon, which targets family and friends of individuals with alcoholism 
(“Center for Substance Use Treatment,” 1999). The integration of peers into these 






Use of Peer Recovery Specialist Services in Healthcare Settings 
In 2010, the Affordable Care Act’s passage included a mandate of mental health 
and substance use services as an essential covered benefit under health insurance 
plans. This inclusion caused the adoption of peer recovery specialists within the 
healthcare industry to increase (Myrick and Vecchio, 2016). Given the heightened 
response of the opioid epidemic by local governments, corresponding legislation 
followed at the federal level that provided funding to state and local governments to 
implement interventions that would curb the epidemic and decrease opioid-related 
deaths. The 21st Century Cures Act was passed in 2016. The legislation provided more 
than 1 billion dollars ($1B) to be distributed to states and local entities through 
SAMHSA. States designed interventions to increase peer recovery specialists as part of 
the healthcare ecosystem. For example, in Indiana, the state used its funds to embed 
peer recovery specialists in emergency departments (Watson et al., 2019). The logic 
behind Indiana’s approach was to identify patients with opioid use disorder to connect 
them to outpatient treatment, commonly known as medication-assisted treatment 
(MAT). The goal of Indiana’s program was to connect the patient to the outpatient 
setting within 48 hours of discharge from the hospital. Additionally, the peers offer 
patients naloxone, a life-saving medication that rapidly reverses an opioid overdose and 
provides them access to sexually transmitted disease testing (Watson et al., 2019). 
 In 2015, Rhode Island’s Overdose Prevention and Intervention Task Force also 
recommended using peer recovery specialists as an intervention to combat the opioid 
epidemic. Like Indiana, Rhode Island used funds provided through SAMHSA to develop 




et al., 2019). Peers were not employed by hospitals but through the largest state-wide 
recovery center in the state. All peer recovery specialists hired were formally certified. 
Peers received referrals through a hotline. Similar to Indiana’s model, once a 
connection is made to a patient, peer recovery specialists work with patients to connect 
them to outpatient treatment centers for follow-up care after discharge from the hospital 
and train patients to administer naloxone (Waye et al., 2019). Healthcare entities are not 
the only source of employers or referral sources into peer recovery services. Other 
states such as Massachusetts leverage the work of police and fire departments to 
identify patients with opioid use disorder to refer them to health care entities that provide 
peer recovery services (Formica et al., 2018).  
Assessing Impact of Peer Recovery Specialist Services in Healthcare Settings  
 The primary logic for the use and development of peer recovery specialists is that 
they can leverage their lived experiences to motivate and convince patients to 
participate in treatment modalities in a way that other healthcare providers may be less 
able. Further, the primary reason for peers to be embedded in and/or receive referrals 
from emergency departments at hospitals is because hospital environments serve as a 
frontline access point to potential opioid overdoses and other related events that result 
from substance use disorder (Masson et al., 2002). Indiana’s program  evaluated its 
success in a six-month pilot. In one emergency department during that time, a total of 
82 patients were engaged with a peer recovery specialist. Thirty-seven patients (44% of 
those engaged) were confirmed to attend at least 1 follow-up appointment while 19 
(23% of those engaged) were still receiving treatment for opioid use after 6 months 




more patients. Peer recovery specialists worked with 1,208 people through the period of 
July 2016 through June 2017. Of the 1,208 people, 51% were connected to treatment, 
which was defined broadly and included but was not limited to inpatient and outpatient 
treatment and medication-assisted treatment. Nearly 90% of all individuals engaged 




 The conceptual framework used for this study builds upon the relationship 
between the OSOP peer recovery specialist and their various stakeholders. These 
stakeholders include the relationship that the peer has with patients, the healthcare 
delivery system, broader patient population, and community/society. This conceptual 
framework depicted in Figure 2 is adapted from the United States Department of Health 
and Human Service’s Agency of Healthcare Research and Quality (AHRQ) 
(Viswanathan et al., 2009). The model was tailored to specifically highlight the 
effectiveness of the role of community health workers; however, as designed, its intent 










Figure 2: Conceptual Framework of Opioid Survivor Outreach Program Peer 
Recovery Specialist Navigation: Detailed perspective into the profile of OSOP 
peer recovery specialist and their impact 


















The literature review identified that a key aspect of community health workers 
and peer recovery specialist roles operating within the healthcare system is their ability 
to serve as a conduit between their lived experiences, the lived experiences of their 


























Patient Characteristics: Demographics (race, ethnicity, linguistics, socio-economic 
status (SES). 
 
Population Characteristics: Approach to intervention, criteria for referral and 
eligibility 
 
Societal Characteristics: Access to substance use services, community-based 
resource and capacity 
Impact / 
Outcomes 
OSOP Peer Recovery Specialist Characteristics: Demographics (race, ethnicity, 
linguistics, socio-economic status (SES), bond with community/target population, 





vulnerable population of those experiencing opioid use disorder and how their life and 
experience can match with the characteristics of the OSOP peer recovery specialist. 
Furthermore, it is plausible that the patient also reflects the societal characteristics of 
the community, which influences them and their interactions with both the OSOP peer 
recovery specialist and the healthcare system. In this framework, the OSOP peer 
recovery specialist receives training that allows them to assist patients in a way that 
reflects their lived experience and ability to connect with the targeted population without 
compromising them as a formal medically trained provider or clinician.  
 These combined attributes allow the use of an analytical framework to assess 
outcomes and impact of the OSOP recovery specialists’ interactions and intervention 
with patients. The research aims of this study test the interaction between the OSOP 
peer recovery specialist and the patient to discern downstream impact on reducing 
avoidable, unnecessary hospital utilization specifically related to opioid use.  
Study Design 
 For this study, a quasi-experimental design was used to compare patients that 
received the OSOP peer recovery specialist intervention to a historical control group of 
patients that did not receive the intervention. The design includes a pre and post-
observation analysis of opioid-related emergency department visits, and observation 
and inpatient admissions for the study group and the historical control group, which was 
determined through the process of propensity score matching by age, race, ethnicity, 
and gender. Data for both sets of patients used in this analysis were retrospectively 
extracted from two main sources – MedStar Health’s electronic record known as 




CRISP is the regional health information exchange system that serves as a central 
hospital utilization data warehouse in Maryland and Washington, D.C. Data collected 
through CRISP included aggregate emergency department, observation, and inpatient 
admission data for the study group population pre and post-enrollment into the OSOP 
program. For the historical control group, aggregate emergency department, 
observation, and inpatient admission data were also collected through CRISP. 
Leveraging CRISP data allows for emergency department, observation and inpatient 
admission data to be collected for the four MedStar hospitals, as well as hospital visits 
for opioid-related events located within the state of Maryland. Further, CRISP also 
served to retrieve a payor source for all patients as part of the study and historical 
control groups.  
Retrospective data were used; therefore, patients were not formally recruited to 
participate in the study.  Patients in the study group included those that were 18+ years 
old, were suspected of an opioid overdose, self-reported opioid use as part of the 
SBIRT screen or were referred to OSOP peer recovery specialist by a member of the 
clinical care team for a consultation. Further, all patients that were engaged with the 
OSOP peer recovery specialist and used within the study sample must include an ICD-
10 diagnosis code related to opioid use, dependence, abuse, and other opioid-related 
events. Opioid-related codes were selected through the recommendations of the 
Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project 
(H-CUP) (Moore and Barrett, 2017). A full list of these diagnosis codes is listed in 
Appendix: Figure 2. Patients that met the criteria had an initial encounter with the 




opioid-related diagnosis were excluded from the study. This exclusion was necessary to 
most appropriately select a historical control group for analysis. The application of this 
inclusion and exclusion criteria allowed for a total of 416 patients to be included as part 
of the study group out of 615. 
The study group was compared to a historical control group that reflects similar 
inclusion criteria based on a set of similar characteristics. The period for patients 
selected for the historical control group was from May 2017 – February 2018. This 
timeframe was deemed appropriate for patient selection because the OSOP program 
was not implemented during this timeframe, but all four hospitals had launched the 
evidence-based SBIRT protocol (Appendix: Figure 1). Patients selected for the 
historical control group included those that were 18+ years old and have an ICD-10 
diagnosis code related to opioid use, dependence, abuse, and other opioid-related 
events (Appendix: Figure 2). Patients in the historical control group were also 
assigned a study enrollment date based on their opioid-related visits to one of the four 
study population hospitals; for patients with multiple hospital opioid-related encounters, 
the earliest encounter within the period of May 2017 – February 2018 was used as the 
enrollment date for the historical control group and used to determine the 12-month 
follow-up period for collecting the outcome data. 
Further, to more appropriately match the intervention group with the historical 
control group, the selection of the historical control group was modeled after like 
characteristics as found in the study group. Specifically, propensity score matching was 
used in selecting the historical control group. These characteristics included race, 




align the study group and the historical control group to reduce bias and mirror a 
randomized control study (Austin, 2011). A full description of the inclusion and exclusion 
criteria for the study and historical control groups can be found in Appendix: Figure 3. 
The study was approved by three Institutional Review Boards (IRBs), including MedStar 
Health Research Institute, Johns Hopkins Bloomberg School of Public Health, and 
Maryland Department of Health.  
Data Analysis 
 A negative binomial regression analysis was used to estimate the association 
between the OSOP intervention, and the expected number of opioid and all-cause 
hospital visits, including emergency department, observation, and inpatient admissions. 
Leveraging the regression technique, a predicted number of opioid-related and all-
cause emergency department, observation, and inpatient admissions were calculated 
over a 12-month pre and post period, which was dictated by the enrollment date of 
individuals in the historical control and study group. Table 2 provides an overview of the 
design in comparing pre and post-period visits for both the historical control and study 
groups. 
Table 2: Overview of Design in Analyzing Hospital Visits of Historical Control and 
Study Groups with Enrollment Dates 
Pre-Enrollment Hospital 
Visits 
Enrollment Date Post-Enrollment 
Hospital Visits  
Hospital visits for 12 months 
before individual enrollment 
date  
Historical Control Group 
May 2017 – February 2018 
Hospital visits for 12 months 
post to individual enrollment 
date 
Hospital visits for 12 months 
before individual enrollment 
date 
Study Group 
March 2018 – July 2019 
Hospital visits for 12 months 






The predicted number of these visits were compared between the pre and post 
periods for the study group, as well as the pre and post periods for the control and study 
groups, respectively. The negative binomial regression model also allows for a 
difference in difference estimation to be conducted. Common in research that includes 
the comparison of two groups before and post a specific intervention, the difference in 
difference estimation allows for the comparison among the groups and intervention 
periods to be assessed (“Difference-in-Difference Estimation,” 2020). 
Figure 3: Difference in Differences Approach 
(“Difference-in-Differences Estimation,” 2020) 
 
This analysis included determining the date of enrollment into OSOP for each 
study group patient by using data collected from MedStar’s electronic medical record. 
The medical record was used to determine other hospital visits at other non-MedStar 
hospitals through CRISP. Further, the novel coronavirus (COVID-19) may have 
impacted hospital visits for the study population. Because this analysis included a 12-




study population between the periods of March 2019 – July 2019 may have been 
impacted by the pandemic. Hospital visits at the onset of COVID-19 rapidly declined 
with the onset of the virus spread in the United States in early March 2020. To account 
for any impact related to COVID-19, a sensitivity analysis was conducted. Those in the 
study group that enrolled between the periods of March 2019 – July 2019 were 
excluded from the analysis. The statistical software used for data analysis was STATA 
16.0. 
Results 
Characteristics of the study population (n=416) are included in Table 3. Among 
those that were included in the study group were 39.66% Black, Other, or Unknown and 
60.34% White. Those in the study population ranged in age from 18 to 83. The mean 
age of participants was 44.43. Of those in the study group, 25.96% were 18-34 years 
old, 31.73% were 35 – 49 years old, 35.82% were 50-64 years old, and 6.49% were 
over the age of 65. Like the study group, the historical control group included 
participants that were 39.66% Black, Other, or Unknown and 60.34% White. Of those 
matched to the historical control group, 25.96% were 18-34 years old, 29.81% were 35 
– 49 years old, 33.17% were 50-64 years old, and 11.06% were over the age of 65. 
65.87%, of those in the study group were male.  
The payor source was also captured using CRISP. For the study population, 
9.29% of those enrolled were covered under commercial plans, 53.85% under Maryland 
Medicaid – Managed Care (MC) plans, 6.01% under Maryland Medicaid – Fee for 
Service (FFS) plan, 14.90% under Medicare FFS, 3.37% under Medicare MC, and 




participants in the study group and 412 in the historical control group. For the historical 
control group, 11.41% of those enrolled were covered under commercial plans, 54.81% 
under Maryland Medicaid – Managed Care (MC) plans, 7.45% under Maryland 
Medicaid – Fee for Service (FFS) plan, 18.03% under Medicare FFS, 2.16% under 
Medicare MC, and 5.05% were noted as self-pay / charity care. The only significant 
differences in demographics between the two groups were those in the category of age 
greater than 65 and those with self-pay insurance. 
Table 3: Patient Characteristics: OSOP Peer Recovery Specialist Study Group and 








Race/Ethnicity    
White 251 (60.34%) 251 (60.34%) 1.00 
Black / Other / 
Unknown 
165 (39.66%) 165 (39.66%) 1.00 
Age    
18-34 years 108 (25.96%) 108 (25.96%) 1.00 
35-49 years 132 (31.73%) 124 (29.81%) 0.55 
50-64 years 149 (35.82%) 138 (33.17%) 0.42 
65+ years 27 (6.49%) 46 (11.06%) 0.02* 
Gender    
Male 274 (65.87%) 274 (65.87%) 1.00 
Female 142 (34.12%) 142 (34.12%) 1.00 
Payor Source (n=409) (n=412)  
Commercial Other 38 (9.29%) 47 (11.41%) 0.30 
MD Medicaid – 
Managed Care 
224 (53.85%) 228 (54.81%) 0.78 
MD Medicaid – FFS 25 (6.01%) 31 (7.45%) 0.40 
Medicare – FFS  62 (14.90%) 75 (18.03%) 0.22 
Medicare – MC 14 (3.37%) 9 (2.16%) 0.29 
Self-Pay / Charity 46 (11.06%) 21 (5.05%) 0.001* 
*p <0.05 
 Descriptive statistics for the historical control and study groups regarding the total 




Table 4. Hospital visits included in the table are an aggregate total of emergency 
department and observation and inpatient admissions. When comparing the pre and 
post periods of the study group, there were decreases in the number of hospital visits in 
all three areas –opioid-related visits, non-opioid-related visits, and all-cause visits. The 
largest percentage decrease when comparing the pre and post-enrollment periods of 
the study group were opioid-related visits, which decreased by 16.8%. The historical 
control group, however, observed an increase in all three visit categories with a 42.1% 
increase in opioid-related visits. 
Table 4: Descriptive Statistics: OSOP Historical Control and Study Groups 











413 1,693 2,106 
Post-Enrollment – 
Historical Control 
587 1,731 2,318 
Pre-Enrollment – 
Study Group 
535 1,146 1,681 
Post-Enrollment – 
Study 
445 1,028 1,473 
Total – Combined 1,980 5,598 7,578 
 
A negative binomial regression model was used to analyze the impact of OSOP 
on hospital utilization trends. Like a Poisson regression model, this technique was used 
because the variance was not equal to the mean of a typical Poisson model. In other 
words, a negative binomial regression model is used when there is evidence of 




regression analysis was then used to calculate the expected number of opioid-related 
and all-cause hospital visits for the historical control and study groups.  
 Table 5 provides the difference-in-difference analysis and coefficients for each 
corresponding variable. These variables listed below were used in the negative binomial 
regression analysis to calculate expected opioid-related and all-cause hospital visits for 
both groups. The regression results found a statistically significant difference between 
the historical control and study groups as it relates to opioid-related visits (Variable: 
Treatment; CE: 0.633; p = 0.001). These results indicate that the study group is known 
to have a higher number of opioid-related visits compared to the historical control group. 
The OSOP intervention was noted to reduce expected opioid-related visits (Variable: 
Interaction; CE: -0.721; p = 0.001).  
Table 5: Negative Binomial Regression of Expected Opioid-Related Hospital Visits  
 
Variable Difference in Differences 





















Table 6 provides results for expected opioid-related visits for the historical control 
and study groups. Though not statistically significant, the results of this analysis observe 
an 8.4% reduction in the expected number of opioid-related hospital visits over a 12-
month period when comparing the study group to the historical control group. This is 
calculated by comparing the number of expected opioid-related visit in the post-
enrollment period of the historical control group of 1.433 (CI: 1.172, 1.692) and the 
study group of 1.312 (CI: 1.064, 1.561)). Statistically significant results were derived 
when comparing the impact on expected opioid-related hospital visits between the pre 
and post-enrollment period of the study population. A 32.2% reduction in the expected 
opioid-related hospital visits after enrollment in OSOP was observed in the study group. 
This is calculated by comparing the number of expected opioid-related visits from the 
study group in the pre-enrollment period, 1.934 (CI: (1.580, 2.288)) to the post-
enrollment period, 1.312 (CI: (1.064, 1.561)).  
Table 6: Expected Opioid-Related Hospital Visits for Historical Control and Study 
Groups with Confidence Interval 
 Expected Visits Confidence Intervals 
Pre-Enrollment – 
Historical Control 
1.027 (0.835, 1.212) 
Post-Enrollment – 
Historical Control 
1.433 (1.172, 1.692) 
Pre-Enrollment – Study 
Group 
1.934 (1.580, 2.288) 





 It is important to note the difference in the results of expected opioid-related visits 
in the historical control group pre and post-enrollment. While the study population 
showed a reduction in the total number of expected opioid-related hospital visits, the 
historical control group saw a significant increase when comparing participants in the 
pre and post periods. The expected number of opioid-related visits increased by 39.5%. 
Figure 4 depicts the same information as presented in Table 6. However, it visually 
demonstrates the reduction in expected opioid-related visits in the study group 
compared to the increase of expected opioid-related visits in the historical control group. 
This divergence of results between the historical control and study groups demonstrated 
the effect of the intervention observed in the study group. 
Figure 4: Expected Counts of Opioid-Related Hospital Visits in 12 Month Period 








































Expected Counts of Opioid-Related Hospital Visits in 12 




The expected number of all-cause hospital visits for the historical control and 
study groups were also analyzed. Table 7 provides the difference in difference analysis 
and coefficients for each corresponding variable for the all-cause hospital visit negative 
binomial regression analysis. When comparing the historical control and study groups, a 
statistically significant difference was not observed in reducing all-cause hospital visits 
(Variable: Interaction; CE: -0.208; p = 0.164) 












Table 8 provides results for expected all-cause visits for the historical control and 
study groups. The results of this analysis observe a 38.9% reduction in the expected 
number of all-cause hospital visits over a 12-month period when comparing the 
historical control and study groups. This is calculated by comparing the number of 
expected all-cause hospital visits in the post-enrollment period of the historical control 
Variable Difference in Differences 





















group of 3.598 (CI:( 2.907, 4.289)) and the study group of 2.200 (CI: (1.757, 2.643). 
Similar results were also derived when comparing the impact on expected all-cause 
hospital visits between the pre and post-enrollment period of the study population. A 
12.0% reduction in the expected all-cause hospital visits after enrollment in OSOP was 
observed.   
Table 8: Expected All-Cause Hospital Visits for Historical Control and Study 
Groups with Confidence Interval 
 Expected Visits Confidence Intervals 
Pre-Enrollment – 
Historical Control 
3.323 (2.687, 3.960) 
Post-Enrollment – 
Historical Control 
3.598 (2.907, 4.289) 
Pre-Enrollment – Study 
Group 
2.501 (2.003, 2.999) 
Post-Enrollment – 
Study 
2.200 (1.757, 2.643) 
 
 
As observed in the analysis of opioid-related visits, it is also relevant to note 
other differences when comparing expected all-cause hospital visits. While the study 
population showed a 12.0% reduction in the expected number of all-cause hospital 
visits, the historical control group saw an 8.3% increase.  Figure 5 depicts the same 
information as presented in Table 8. However, it visually demonstrates the reduction in 
expected all-cause hospital visits in the study group compared to the increase of 
expected all-cause hospital visits in the historical control group. This phenomenon 





Figure 5: Expected All-Cause Hospital Visits for Historical Control and Study 
Groups with Confidence Interval 
 
Leveraging this negative binomial regression analysis, a predicted number of 
opioid-related hospital visits were calculated. The predicted number of these visits were 
compared between the pre and post periods for the study group, as well as the pre and 
post periods for the control and study groups, respectively. Table 9 outlines these 
results in predicting less than or equal to 1, 2, 3, 4, or 5 opioid-related visits over a 12-
month period. Among those in the study group, 59.4% of patients were predicted to 
have less than or equal to one opioid-related visit before enrollment into OSOP. 
Following enrollment in OSOP, 69.3% of patients were predicted to have less than or 
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enrollment in OSOP through 5 visits, although not as drastic of predicted probability as 
that observed in the less than or equal to one visit. 
Among those in the control group, 75.1% of patients were predicted to have less 
than or equal to one opioid-related visit before their selected enrollment date. Following 
their enrollment date, 67.1% of patients were predicted to have less than or equal to 
one opioid-related visit. Specifically, the observations for the historical control group can 
be interpreted as patients having less than or equal to 1 visit for an opioid-related event 
in the pre-enrollment period than in the post-enrollment period. These trends continue 
when comparing pre and post-enrollment through 5 visits, although not as drastic of 
predicted probability at less than or equal to one visit. Similarly, among those in the post 
period of the control group, 67.1% of patients were predicted to have less than or equal 
to one opioid-related visit post-enrollment compared to 69.3% of patients in the study 
period following enrollment in OSOP.  
Table 9: Predicted Probability of Opioid-Related Visits Over 12-Month Period with 
Confidence Intervals 
Predicted Probability of Opioid-Related Visits over 12-month period (CI) 
Treatment 
Group 
Less < =1 
Visit 
Less < =2 
Visits 
































































COVID-19 Sensitivity Analysis  
To account for any impact related to COVID-19, a sensitivity analysis was 
conducted. Those in the study group that enrolled between the periods of March 2019 – 
July 2019 were excluded. After these exclusions, a total of 139 patients were removed 
from the study population. Table 10 provides the difference in difference analysis and 
coefficients for each corresponding variable for expected opioid-related visits. These 
variables listed below were used in the negative binomial regression analysis to 
calculate expected opioid-related and all-cause hospital visits for both groups. Table 11 
provides the results when analyzing expected opioid-related hospital visits. The OSOP 
intervention was found to reduce opioid-related events when comparing the two groups 
(Variable: Interaction; CE: -0.833; p = 0.001). The study group pre and post-enrollment, 
although not statistically significant, showed a 39.3% decrease in the expected opioid-
related visits. This is slightly larger than the 32.2% reduction observed when included 

























Table 11: COVID-19 Sensitivity Analysis: Expected Opioid-Related Hospital Visits 
for Historical Control and Study Groups with Confidence Interval 
 Expected Visits Confidence Intervals 
Pre-Enrollment – 
Historical Control 
1.105 (0.875, 1.334) 
Post-Enrollment – 
Historical Control 
1.542 (1.227, 1.858) 
Pre-Enrollment – Study 
Group 
2.425 (1.824, 3.026) 
Post-Enrollment – 
Study Group 
1.472 (1.090, 1.854) 
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The same analysis was completed for all-cause hospital visits. Table 12 provides 
the difference in difference analysis and coefficients for each corresponding variable for 
expected all-cause hospital visits. Table 13 provides the results when analyzing 
expected all-cause hospital visits. The OSOP intervention was found to not have a 
statistical significance on reducing all-cause hospital events when comparing the two 
groups (Variable: Interaction; CE: -0.177; p = 0.308). The study group pre and post-
enrollment, although not statistically significant, showed a similar reduction in expected 
all-cause hospital visits. In the full analysis, the reduction in expected all-cause hospital 
visits was 12% when comparing pre and post-enrollment of the study group versus the 
9% reduction when comparing pre and post-enrollment of the study group in this 
analysis. 
Table 12: COVID-19 Sensitivity Analysis: Negative Binomial Regression of 
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Table 13: COVID-19 Sensitivity Analysis: Expected All-Cause Hospital Visits for 
Historical Control and Study Groups with Confidence Interval 
 Expected Visits Confidence Interval 
Pre-Enrollment – 
Historical Control 
3.450 (2.761, 4.140) 
Post-Enrollment – 
Historical Control 
3.738 (2.988, 4.488) 
Pre-Enrollment – Study 
Group 
2.978 (2.235, 3.720) 
Post-Enrollment – Study 2.703 (2.016, 3.390) 
 
Discussion of Results  
 The results of this analysis indicate that with the implementation of OSOP, there 
is an observed effect in reducing emergency department visits, as well as observation 
and inpatient admissions for both opioid-related and all-cause events. The results of this 
study conclude that the OSOP intervention assists in reducing opioid-related visits, and 
these results are statistically significant. Specifically, there is a statistically significant 
32.5% reduction in expected opioid-related visits pre and post-enrollment when 
analyzing the study group. Though not statistically significant, the results of this analysis 
observe an 8.4% reduction in the expected number of opioid related hospital visits over 
a 12-month period when comparing the historical control and study groups. These 
reductions are especially compelling as it’s important to note that those in the study 





Pertaining to all-cause hospital visits, the results demonstrate an observed but 
not statistically significant 12.0% reduction in all-cause hospital visits pre and post-
enrollment into OSOP. There was a statistically significant 38.9% reduction in all-cause 
visits between the historical and control group. A sensitivity analysis conducted to 
examine the potential impact of hospital visits for patients enrolled in OSOP during the 
period of COVID-19 demonstrated even stronger results and reductions in expected 
opioid-related and all-cause hospital visits. These findings support the hypothesis of the 
study that the OSOP peer recovery specialist can support reducing subsequent hospital 
visits by offering a variety of different supports to participating patients, including referral 
to substance use treatment, access to harm reduction tools (e.g. naloxone), and 
education on opioid-use. 
Strengths and Limitations 
 This analysis of the impact of the OSOP peer recovery specialists on patient 
utilization carries several strengths that support the external validity of the study. First, 
the study population, targeted as opioid overdose survivors, reflects a similar 
demographic when comparing opioid-related overdose deaths in Maryland. Specifically, 
the study population was 66% male. In 2018, males accounted for 73% of all opioid-
related deaths in Maryland. The study population also was 60% White, and 33% Black 
compared to opioid-related deaths in Maryland in 2018 being represented by 63% 
White, and 34% Black, respectively (“Opioid Overdose Deaths,” 2020). While this study 
may not be generalizable to other areas in the country, the characteristics of those 
included in the study group enhance its generalizability for assessment and broad 




similar when comparing the study population and the historical group. While payor 
source could not be derived for all study participants, Medicaid FFS or MC made up 
59.9% of the study population and 62.3% of the historical control group. Medicare FFS 
or MC enrollees accounted for 18.3% of the study population and 20.2% of the historical 
control group. 
 External validity is also strengthened using CRISP hospital utilization data. 
CRISP data allows for the analysis to incorporate hospital visits by patients at any 
hospital facility in the state of Maryland. The use of these data adds validity by including 
statewide hospital visit data rather than hospital visits exclusive to MedStar Health 
hospital facilities. However, if a patient visited a hospital in neighboring states such as 
Pennsylvania or West Virginia, this utilization would not be captured on CRISP or other 
regional health information exchange platforms. 
The analysis of the impact of the OSOP peer recovery specialists on patient 
utilization carries several limitations and vulnerabilities, including study design, secular 
trends, and coding and/or documentation accuracy. First, as a quasi-experimental 
study, the study and historical control groups were not selected or analyzed as a formal 
randomized control trial. The use of propensity score matching helps to address this 
limitation, although this type of study nevertheless poses threats to both the internal and 
external validity (Campbell and Stanley, 1963). Relating to internal validity, the selection 
period of the historical control group was before the implementation of the OSOP 
program, but during a period in which the SBIRT protocol was already live. Thus, some 
patients included within the historical control group may have received assistance from 




between the other peer recovery specialists staffed in the emergency department 
versus the OSOP peer recovery specialist is the intensive nature, duration, and 
resource provided through OSOP.   
 It is also reasonable to think that the study population was more at risk than 
those in the historical control group because of the role of secular trends, specifically, 
the increase of availability and accessibility of fentanyl. It was necessary to select the 
historical control group that met the inclusion and exclusion criteria as close as possible 
to when OSOP went live at each of the hospitals within this study. As cited earlier, 
opioid-related deaths in Maryland have been increasing since 2010. According to the 
Centers for Disease Control and Prevention (CDC), Maryland experienced 504 opioid-
related deaths in 2010 compared to 2,087 deaths in 2018 (“National Institute on Drug 
Abuse,” 2019). However, it is important to understand the rise in deaths related to 
fentanyl. Fentanyl is a synthetic opioid that is known to be more potent than other 
opioids such as heroin or prescription drugs. In 2015, fentanyl-related deaths in 
Maryland totaled 340. The selection of the historical control group began during 2017. 
However, hospital-visit data for pre-enrollment visit analysis began in 2016. In 2016, 
fentanyl-related deaths in Maryland jumped 229% totaling 1,119. In 2017, the number 
continued to climb to 1,594. In 2018, fentanyl-related deaths in Maryland skyrocketed to 
1,888 (Appendix: Figure 5). Baltimore City, the primary location of hospitals and 
patients in the setting of this study had the most fentanyl-related deaths with 758 
(“Maryland Department of Health, 2019). This is an example of how the changes in the 
drug market may have influenced an assessment of patient utilization of hospital 




 Another secular trend that may have impacted the results was the impact of the 
coronavirus disease 2019 (COVID-19) pandemic for patients enrolled in OSOP from 
March 2019 – July 2019. The global pandemic altered the nature of communities 
accessing hospital services, such as visiting the emergency department beginning in 
late March or early April. The fear of transmission of COVID-19 by visiting a hospital 
may have caused an unknown reduction in the number of opioid-related or all-cause 
hospital visits in the post-enrollment period for the study group. On the contrary, during 
this time, there may have been an increased chance for relapse due to the social 
consequences of COVID-19, such as isolation. While it is too early to know COVID-19’s 
impact on opioid overdoses, as well as corresponding hospital visits, initial data from the 
University of Baltimore shows that opioid overdoses increased by almost 20% from the 
state day of mandated state restrictions (Alter and Yeager, 2020). The historical control 
group and pre-enrollment study group hospital visits would not have been influenced by 
COVID-19.  The sensitivity analysis conducted demonstrated that reductions of 
expected opioid-related visits were more significant when excluding patients that may 
have been impacted by the pandemic. 
Another limitation of this study is assessing patient utilization through opioid-
related events with the ICD-10 diagnostic codes as the source of the assessment. 
Relying on diagnostic codes for this study is dependent on the accuracy of the coding 
and documentation. In this study, the use of coding data may underreport the number of 
opioid-related emergency department visits, and observation and inpatient admissions. 
This can be a result if coding is based on presenting symptoms. For example, if the 




does not assign a final diagnosis code related to an opioid-related event the patient 
would not have been selected for the study. This is especially true as CRISP served as 
a key data source for data to be analyzed. Patient emergency department, inpatient, or 
observation visits from CRISP only included up to six specific codes per visit. 
Future Research  
 Since the launch of OSOP at the four hospitals in this study, five other acute care 
facilities within MedStar have now implemented the program since late 2019. These 
hospitals are located outside the Baltimore region, such as hospitals in other 
jurisdictions of Maryland and Washington, DC. The training of OSOP peer recovery 
specialists and hospital clinicians was modeled after the original OSOP implementation 
in the four hospitals within this study. As their implementation matures, additional 
patient utilization data could be used to determine a more robust, regional assessment. 
Data could also be assessed for non-opioid related visits to inform hospital utilization 
trends on the impact of OSOP for all-cause hospital visits. One may hypothesize that 
even though the OSOP intervention is geared toward addressing opioid use disorder, 
the OSOP peer recovery specialists may also assist patients in navigating patients for 
other specialty service needs. As this study was also focused on assessing patient 
utilization over a pre and post-enrollment period of one-year, additional research could 
examine whether the reduction in hospital visits continues after the one-year post-
enrollment, especially with the vulnerability of the study population to relapse.  
Designing future methods of evaluation of this program may include studying the 
change in hospital visits from specific interventions that patients received. For example, 




recovery specialist to medication therapy for opioid use, such as buprenorphine, 
naltrexone, or methadone resulted in a greater impact or reduction of hospital-related 
visits than patients that did not receive such treatments. On a similar note, future 
research may seek to implement the expansion of providers eligible to provide these 
medication therapies. Additionally, more robust data regarding other psychosocial or 
clinical conditions may clarify the underlying drivers to both opioid use and hospital 
utilization. Future programmatic improvements to research systemic drivers may be to 
include incorporating a social needs assessment tool to begin tracking the specific 
needs of this vulnerable patient population. 
Conclusion 
 The ability to identify and effectively evaluate the efficacy of interventions that 
states, local jurisdictions, and hospitals have implemented to combat the opioid 
epidemic is critical in determining whether such investments are making an impact. In 
an era of constrained federal and state funds, it is important to use public health funding 
wisely to help eradicate the opioid epidemic in Maryland and across the country. This 
study suggests that the Opioid Survivor Outreach Program peer recovery specialist, 
which provides several supportive services and resources to patients – the connection 
of shared lived experiences, referrals to treatment programs, naloxone, education on 
opioid-use – is effective in reducing opioid-related and all-cause hospital visits. These 
results validate OSOP as an effective intervention to engage opioid overdose survivors 
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Figure 1: Screening, Brief Intervention, and Referral to Treatment Components 
(“Evidence Supporting the Effectiveness of SBIRT,” 2011) 
 
Figure 2: ICD-10 Opioid-Related Diagnostic Codes  
(“Opioid-Related Codes Hospital Use,” 2019) 
ICD-10-CM 
Code ICD-10-CM Description 
F11.10 Opioid abuse, uncomplicated 
F11.120 Opioid abuse with intoxication, uncomplicated 
F11.121 Opioid abuse with intoxication delirium 
F11.122 Opioid abuse with intoxication with perceptual disturbance 
F11.129 Opioid abuse with intoxication, unspecified 
F11.14 Opioid abuse with opioid-induced mood disorder 
F11.150 Opioid abuse with opioid-induced psychotic disorder with delusions 
F11.151 Opioid abuse with opioid-induced psychotic disorder with hallucinations 
F11.159 Opioid abuse with opioid-induced psychotic disorder, unspecified 
F11.181 Opioid abuse with opioid-induced sexual dysfunction 
F11.182 Opioid abuse with opioid-induced sleep disorder 
F11.188 Opioid abuse with other opioid-induced disorder 
F11.19 Opioid abuse with unspecified opioid-induced disorder 
F11.20 Opioid dependence, uncomplicated 
F11.220 Opioid dependence with intoxication, uncomplicated 
F11.221 Opioid dependence with intoxication delirium 
F11.222 Opioid dependence with intoxication with perceptual disturbance 
F11.229 Opioid dependence with intoxication, unspecified 
F11.23 Opioid dependence with withdrawal 
F11.24 Opioid dependence with opioid-induced mood disorder 




F11.251 Opioid dependence with opioid-induced psychotic disorder with hallucinations 
F11.259 Opioid dependence with opioid-induced psychotic disorder, unspecified 
F11.281 Opioid dependence with opioid-induced sexual dysfunction 
F11.282 Opioid dependence with opioid-induced sleep disorder 
F11.288 Opioid dependence with other opioid-induced disorder 
F11.29 Opioid dependence with unspecified opioid-induced disorder 
F11.90 Opioid use, unspecified, uncomplicated 
F11.920 Opioid use, unspecified, with intoxication, uncomplicated 
F11.921 Opioid use, unspecified, with intoxication delirium 
F11.922 Opioid use, unspecified, with intoxication with perceptual disturbance 
F11.929 Opioid use, unspecified, with intoxication, unspecified 
F11.93 Opioid use, unspecified with withdrawal 
F11.94 Opioid use, unspecified with opioid-induced mood disorder 
F11.950 Opioid use, unspecified with opioid-induced psychotic disorder with delusions 
F11.951 Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations 
F11.959 Opioid use, unspecified with opioid-induced psychotic disorder, unspecified 
F11.981 Opioid use, unspecified with opioid-induced sexual dysfunction 
F11.982 Opioid use, unspecified with opioid-induced sleep disorder 
F11.988 Opioid use, unspecified with other opioid-induced 
F11.99 Opioid use, unspecified with unspecified opioid-induced disorder 
T40.0X1A Poisoning by opium, accidental (unintentional), initial encounter 
T40.0X1D Poisoning by opium, accidental (unintentional), subsequent encounter 
T40.0X1S Poisoning by opium, accidental (unintentional), sequela 
T40.0X4A Poisoning by opium, undetermined, initial encounter 
T40.0X4D Poisoning by opium, undetermined, subsequent encounter 
T40.0X4S Poisoning by opium, undetermined, sequela 
T40.0X5A Adverse effect of opium,  initial encounter 
T40.0X5D Adverse effect of opium, subsequent encounter 
T40.0X5S Adverse effect of opium, sequela 
T40.1X1A Poisoning by heroin, accidental (unintentional), initial encounter 
T40.1X1D Poisoning by heroin, accidental (unintentional), subsequent encounter 
T40.1X1S Poisoning by heroin, accidental (unintentional), sequela 
T40.1X4A Poisoning by heroin, undetermined, initial encounter 
T40.1X4D Poisoning by heroin, undetermined, subsequent encounter 
T40.1X4S Poisoning by heroin, undetermined, sequela 
T40.2X1A Poisoning by other opioids, accidental (unintentional), initial encounter 
T40.2X1D Poisoning by other opioids, accidental (unintentional), subsequent encounter 
T40.2X1S Poisoning by other opioids, accidental (unintentional), sequela 
T40.2X4A Poisoning by other opioids, undetermined, initial encounter 
T40.2X4D Poisoning by other opioids, undetermined, subsequent encounter 
T40.2X4S Poisoning by other opioids, undetermined, sequela 
T40.2X5A Adverse effect of other opioids,  initial encounter 




T40.2X5S Adverse effect of other opioids, sequela 
T40.3X1A Poisoning by methadone, accidental (unintentional), initial encounter 
T40.3X1D Poisoning by methadone, accidental (unintentional), subsequent encounter 
T40.3X1S Poisoning by methadone, accidental (unintentional), sequela 
T40.3X4A Poisoning by methadone, undetermined, initial encounter 
T40.3X4D Poisoning by methadone, undetermined, subsequent encounter 
T40.3X4S Poisoning by methadone, undetermined, sequela 
T40.3X5A Adverse effect of methadone,  initial encounter 
T40.3X5D Adverse effect of methadone, subsequent encounter 
T40.3X5S Adverse effect of methadone, sequela 
T40.4X1A Poisoning by synthetic narcotics, accidental (unintentional), initial encounter 
T40.4X1D Poisoning by synthetic narcotics, accidental (unintentional), subsequent encounter 
T40.4X1S Poisoning by synthetic narcotics, accidental (unintentional), sequela 
T40.4X4A Poisoning by synthetic narcotics, undetermined, initial encounter 
T40.4X4D Poisoning by synthetic narcotics, undetermined, subsequent encounter 
T40.4X4S Poisoning by synthetic narcotics, undetermined, sequela 
T40.4X5A Adverse effect of synthetic narcotics,  initial encounter 
T40.4X5D Adverse effect of synthetic narcotic, subsequent encounter 
T40.4X5S Adverse effect of synthetic narcotic, sequela 
T40.601A Poisoning by unspecified narcotics, accidental (unintentional), initial encounter 
T40.601D 
Poisoning by unspecified narcotics, accidental (unintentional), subsequent 
encounter 
T40.601S Poisoning by unspecified narcotics, accidental (unintentional), sequela 
T40.604A Poisoning by unspecified narcotics, undetermined, initial encounter 
T40.604D Poisoning by unspecified narcotics, undetermined, subsequent encounter 
T40.604S Poisoning by unspecified narcotics, undetermined, sequela 
T40.605A Adverse effect of unspecified narcotics,  initial encounter 
T40.605D Adverse effect of unspecified narcotics, subsequent encounter 
T40.605S Adverse effect of unspecified narcotics, sequela 
T40.691A Poisoning by other narcotics, accidental (unintentional), initial encounter 
T40.691D Poisoning by other narcotics, accidental (unintentional), subsequent encounter 
T40.691S Poisoning by other narcotics, accidental (unintentional), sequela 
T40.694A Poisoning by other narcotics, undetermined, initial encounter 
T40.694D Poisoning by other narcotics, undetermined, subsequent encounter 
T40.694S Poisoning by other narcotics, undetermined, sequela 
T40.695A Adverse effect of other narcotics,  initial encounter 
T40.695D Adverse effect of other narcotics, subsequent encounter 
T40.695S Adverse effect of other narcotics, sequela 
T40.0X2A Poisoning by opium, intentional self-harm, initial encounter 
T40.0X2D Poisoning by opium, intentional self-harm, subsequent encounter                
T40.0X2S Poisoning by opium, intentional l self-harm, sequela      
T40.0X3A Poisoning by opium, assault, initial encounter 




T40.0X3S Poisoning by opium, , assault, sequela      
T40.1X2A Poisoning by heroin, intentional self-harm, initial encounter 
T40.1X2D Poisoning by heroin, intentional self-harm, subsequent encounter 
T40.1X2S Poisoning by heroin, intentional self-harm, sequela 
T40.1X3A Poisoning by heroin, assault, initial encounter 
T40.1X3D Poisoning by heroin, assault, subsequent encounter 
T40.1X3S Poisoning by heroin, assault, sequela 
T40.2X2A Poisoning by other opioids, intentional self-harm, initial encounter 
T40.2X2D Poisoning by other opioids, intentional self-harm, subsequent encounter 
T40.2X2S Poisoning by other opioids, intentional self-harm, sequela 
T40.2X3A Poisoning by other opioids, assault, initial encounter 
T40.2X3D Poisoning by other opioids, assault, subsequent encounter                
T40.2X3S Poisoning by other opioids, assault, sequela 
T40.3X2A Poisoning by methadone, intentional self-harm, initial encounter 
T40.3X2D Poisoning by methadone, intentional self-harm, subsequent encounter 
T40.3X2S Poisoning by methadone, intentional self-harm, sequela encounter 
T40.3X3A Poisoning by methadone, assault, initial encounter 
T40.3X3D Poisoning by methadone, assault, subsequent encounter 
T40.3X3S Poisoning by methadone, assault, sequela encounter 
T40.4X2A Poisoning by other synthetic narcotics, intentional self-harm, initial encounter 
T40.4X2D Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter 
T40.4X2S Poisoning by other synthetic narcotics, intentional self-harm, sequela 
T40.4X3A Poisoning by other synthetic narcotics, assault, initial encounter 
T40.4X3D Poisoning by other synthetic narcotics, assault, subsequent encounter 
T40.4X3S Poisoning by other synthetic narcotics, assault, sequela 
T40.602A Poisoning by unspecified narcotics, intentional self-harm, initial encounter 
T40.602D Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter 
T40.602S Poisoning by unspecified narcotics, intentional self-harm, sequela encounter 
T40.603A Poisoning by unspecified narcotics, assault, initial encounter 
T40.603D Poisoning by unspecified narcotics, assault, subsequent encounter  
T40.603S Poisoning by unspecified narcotics, assault, sequela 
T40.692A Poisoning by other narcotics, intentional self-harm, initial encounter 
T40.692D Poisoning by other narcotics, intentional self-harm, subsequent encounter 
T40.692S Poisoning by other narcotics, intentional self-harm, sequela 
T40.693A Poisoning by other narcotics, assault, initial encounter 
T40.693D Poisoning by other narcotics, assault, subsequent encounter 












18+ years of age <18 years of age 
Enrolled/consented to OSOP program 
via SBIRT screen, referral from clinician, 
suspected overdose  
Enrolled, consented to OSOP program 
via SBIRT screen, referral from clinician, 
suspected overdose, but without ICD-10 
diagnosis-specific to opioid-related event 
at time of enrollment/consent to OSOP 
program 
Emergency Department visit at 4 study 
setting hospitals – MedStar Harbor 
Hospital, MedStar Union Memorial 
Hospital, MedStar Good Samaritan 
Hospital, MedStar Franklin Square 
Medical Center during the time period of 
March 2018-July 2019 
 
ICD-10 diagnosis code specific to opioid-
related event at the time of 
enrollment/consent to OSOP program – 
Appendix: Figure 2 
 
Historical Control Group 
18+ years of age  <18 years of age 
Did not enroll in OSOP program ICD-10 diagnosis-specific to opioid-
related event not present 
Emergency Department visit at 4 study 
setting hospitals – MedStar Harbor 
Hospital, MedStar Union Memorial 
Hospital, MedStar Good Samaritan 
Hospital, MedStar Franklin Square 
Medical Center – during the time period 
of May 2017 – February 2018 
 
ICD-10 diagnosis code specific to opioid-







Figure 4: Fentanyl-Related Deaths in Maryland by Year 










Chapter 2: Engaging Opioid Overdose Survivors: Impact of Peer Recovery 
Specialists on Health System Cost Avoidance 
Abstract 
Objectives: To evaluate the impact of Opioid Survivor Outreach Program (OSOP) peer 
recovery specialist intervention on opioid-related and all-cause hospital charges.  
Design: Program evaluation with a study and historical control group using propensity 
score matching. A difference of means statistical analysis was completed to assess the 
differences in charges on opioid-related and non-opioid related visits. Aggregate 
charges were then analyzed to determine differences between pre and post-enrollment 
periods of both groups. 
Setting: Four hospitals in urban and suburban areas of Baltimore, Maryland metro 
region. 
Participants: There were 416 patients in the study group that received the OSOP 
intervention. Individuals are identified primarily in the emergency department and are 
known opioid overdose survivors. A historical control group of 416 individuals was used 
to compare results. 
Intervention: OSOP provides peer recovery specialist services to patients, including 
opioid education, harm reduction tools, and refers and/or links patients to substance use 
treatment and recovery support services. 
Main Outcome Measure: Associated hospital charges of opioid-related and all-cause 
hospital visits.  
Results: The results of this research demonstrate that opioid-related visits result in an 




visits. When analyzing gross charges and considering the annual costs to operate the 
OSOP program, the OSOP program allows the healthcare system to avoid $1.1M in 
opioid-related hospital charges over one year and $770K in all-cause hospital charges. 
Conclusions: The results suggest that the OSOP peer recovery specialist, which 
provides several supportive services and resources to patients is effective in reducing 
opioid-related and all-cause hospital visits and is an effective cost-avoidance strategy 




















Introduction and Statement of the Problem 
Opioid-related deaths in Maryland have been increasing since the year of 2010. 
According to the Centers for Disease Control (CDC), Maryland experienced 504 opioid-
related deaths in 2010 compared to 2,087 deaths in 2018 (“National Institute on Drug 
Abuse,” 2019). Chapter 1 outlined the important role that hospitals play in responding to 
the opioid epidemic. In reviewing opioid-related data in Maryland and Massachusetts, 
most patients that experienced a fatal opioid-overdose had at least one opioid-related 
visit to a hospital before their fatality (Holler, 2016; Tobin, 2020). States have utilized 
funds from the 21st Century Cures Act of 2016 to deploy opioid-related interventions 
within hospital settings. The focus of this research is to determine the effectiveness of 
one of those programs, the Opioid Survivor Outreach Program (OSOP).  
The OSOP peer recovery specialist conducts a multi-pronged effort as part of the 
intervention, which on average is an engagement with patients of 30-90 days. Without 
the OSOP peer recovery specialist as an integrated member of the healthcare team, 
those experiencing an opioid overdose event would not receive any of the navigation 
services in the hospital or post-discharge (Hollar, 2016). Implementation of the program 
at MedStar Health was first launched in the Baltimore regional hospitals – MedStar 
Harbor Hospital, MedStar Good Samaritan Hospital, MedStar Union Memorial Hospital, 
and MedStar Franklin Square Medical Center. There were 416 patients included in this 
study.  
Chapter 1 sought to explore the relationship of patients enrolling in OSOP and its 
impact on hospital visits. The results found that enrollment in OSOP reduces the 




chapter explores the value of cost avoidance to a health system for the reduction of 
these subsequent visits. This aim is relevant to the policy and practice implications of 
the OSOP program. Specifically, Maryland has a unique all-payer model whereby a 
state-run rate commission sets hospital rates under a global budget revenue system. 
Known currently as Total Cost of Care, the goals of  the model are to reduce overall per 
capita spending, improve quality, reduce hospital-acquired conditions, and focus on 
rooting out spending through initiatives that reduce readmissions and potentially 
avoidable utilization (Maryland All-Payer Model 2020). Maryland defines potentially 
avoidable utilization as “hospital care that is unplanned and can be prevented through 
improved care, care coordination, or effective community-based care or care cost 
increases that result from a potentially preventable complication occurring in a hospital” 
(“Health Services Cost Review Commission,” 2014). Additionally, as part of the Total 
Cost of Care model, it encourages a hospital to focus on population health initiatives in 
three areas in partnership with state agencies – behavioral health, including both mental 
health and substance use, diabetes, and care for medically complex older adults 
(“Maryland’s Total Cost of Care Model,” 2017).  
Assessing the impact of OSOP from a cost avoidance perspective offers the 
ability to determine its financial value because of its success in reducing emergency, 
observation, and inpatient opioid-related hospital visits. No studies have been done to 
evaluate the financial value proposition of the OSOP program. Therefore, the research 
aim of this Chapter is to fill this gap within the literature and ascertain the value of cost 
avoidance for the health system by implementing OSOP. This research seeks to answer 




1. Given the reduction of subsequent hospital-related visits found in Chapter 1 
by enrolling in OSOP, what was the difference of opioid-related and all-cause 
hospital visit costs for patients receiving the OSOP intervention compared to 
a historical control group of patients that did not? 
2. What is the net total cost avoidance benefit (value) to the health system after 
accounting for operational costs to implement and sustain the program? 
Literature Review 
As outlined in Chapter 1, the rapid adoption of peer recovery specialist programs, 
ignited by funding from the 21st Century Cares Act in 2016 to states to address the 
opioid epidemic has led to only a handful of studies that evaluate impact. Most of the 
evaluation studies are based on process-metrics. For example, Indiana’s 
implementation of a peer recovery program receives referrals from hospital emergency 
departments through a call center, which then dispatches them to that site. Like OSOP, 
the program looks to connect patients to outpatient treatment centers for follow-up care 
after discharge from the hospital and train patients to administer naloxone (Waye et al., 
2019). Indiana’s program evaluated its success in a six-month pilot. In one emergency 
department during that time, a total of 82 patients were engaged with a peer recovery 
specialist. Thirty-seven patients (44% of those engaged) were confirmed to attend at 
least 1 follow-up appointment while 19 (23% of those engaged) were still receiving 
treatment for opioid use after 6 months (Watson et al., 2019). A similar process-metric 
oriented study in Rhode Island issued similar results. Rhode Island’s evaluation yielded 
similar results with significantly more patients. Peer recovery specialists worked with 




51% were connected to treatment, which was defined broadly and included but was not 
limited to inpatient and outpatient treatment and medication-assisted treatment. Nearly 
90% of all individuals engaged received training to administer naloxone and were 
provided naloxone kits (Waye et al., 2019).  
The literature on assessing peer recovery specialist programs, specific to 
substance use support for patients, in addition to determining their impact on avoiding 
cost to the health system, is scant. However, studies have demonstrated that healthcare 
systems that have better mechanisms to identify people with opioid use disorder and 
connect them to treatment in outpatient settings can reduce rates of mortality and 
healthcare expenditures. While reviewing charts of 3,000+ patients with opioid use 
and/or dependence, Masson et. al (2002) found that people with opioid use disorder use 
the emergency department for overdose-related events, as well as for care associated 
with their opioid use such as infections. Healthcare expenditures for these patients were 
more than double in a comparison of patients that did not include opioid users (Masson 
et al., 2002). It is important to note that this study did not use a peer recovery specialist 
as an intervention.  
Another research study assessed the difference in healthcare costs for patients 
with opioid dependence that received medication treatment – methadone, 
buprenorphine, and naltrexone – versus patients that did not receive any medication. An 
assessment of almost 13,316 patients showed total health care costs, including hospital 
visits and pharmacy costs, were 29% lower for patients that received one form of these 
medication treatments (Baser, Chalk, Fiellin, & Gastfriend, 2011). In a more recent, 




connection to these medication treatments reduced hospital visits and overall 
healthcare costs, although not statistically significant, when reviewing 6,000 beneficiary 
records (Mohlman et. al., 2016). The results of both studies have strong ties in the 
consideration of assessing OSOP’s role in generating cost avoidance to the health 
system. One of the key aspects of the role of the OSOP peer recovery specialist is to 
build a rapport with the patients to encourage treatment. Referrals and linkages to 
providers that provided these medication treatment modalities are often facilitated 
through the OSOP peer recovery specialist. 
Methods 
Study Design 
For this research aim, a quasi-experimental design was used to compare 
patients that received the OSOP peer recovery specialist intervention to a historical 
control group of patients that did not receive the intervention. Data for this analysis was 
provided through the Chesapeake Regional Information System for our Patients 
(CRISP). CRISP is the regional health information exchange system that serves as a 
central hospital utilization data warehouse in Maryland and Washington, D.C. 
Specifically, the data acquired through CRISP provided the gross patient charges per 
encounter for all opioid-related and non-opioid related emergency department visits and 
observation and inpatient admissions for the pre and post-encounter periods for both 
the study and historical control groups. Operational costs to facilitate the program were 
provided by MedStar Health’s finance team. These costs will be used in the analysis of 
this research to help calculate an overall net value of health system cost avoidance. The 




1 and listed below in Figure 1. The study was approved by three Institutional Review 
Boards (IRBs), including MedStar Health Research Institute, Johns Hopkins Bloomberg 
School of Public Health, and Maryland Department of Health. 
Table 1: Inclusion and Exclusion Criteria – Historical Control and Study Groups 
Study Group 
Inclusion Exclusion 
18+ years of age <18 years of age 
Enrolled/consented to OSOP program via 
SBIRT screen, referral from clinician, 
suspected overdose  
Enrolled, consented to OSOP program via 
SBIRT screen, referral from clinician, 
suspected overdose, but without ICD-10 
diagnosis-specific to opioid-related event 
at time of enrollment/consent to OSOP 
program 
Emergency Department visit at 4 study 
setting hospitals – MedStar Harbor 
Hospital, MedStar Union Memorial 
Hospital, MedStar Good Samaritan 
Hospital, MedStar Franklin Square 
Medical Center during the time period of 
March 2018-July 2019 
 
ICD-10 diagnosis code specific to opioid-
related event at the time of 
enrollment/consent to OSOP program 
 
Historical Control Group 
18+ years of age  <18 years of age 
Did not enroll in OSOP program ICD-10 diagnosis-specific to opioid-related 
event not present 
Emergency Department visit at 4 study 
setting hospitals – MedStar Harbor 
Hospital, MedStar Union Memorial 
Hospital, MedStar Good Samaritan 
Hospital, MedStar Franklin Square 
Medical Center – during the time period of 
May 2017 – February 2018 
 












Data Analysis  
 
The analysis included two parts. The first part included tests to understand the 
differences in the average hospital charges between opioid-related and all-cause 
hospital visits between the historical control and study groups. The first test was to 
calculate an average charge for opioid-related and non-opioid related hospital visits. 
This analysis was completed to validate existing literature for the historical control group 
and study populations, which previously found that opioid-related visits tend to be 
associated with more hospital charges (Masson et. al, 2002). To improve statistical 
significance, all opioid-related and all-cause hospital visits were analyzed across both 
pre and post-enrollment periods of the historical control and study groups. A two-sample 
t-test was conducted to determine the difference in means. Table 2 provides an 
overview of the design as replicated from Chapter 1 in analyzing opioid-related and all-
cause hospital visits. For this analysis, hospital visit charges in the pre and post-
enrollment periods are dictated by the enrollment date of the individuals in the historical 
control and study groups.  
Table 2: Overview of Design in Analyzing Hospital Visit Charges of Historical 
Control and Study Groups with Enrollment Dates 
Pre-Enrollment Hospital 
Visits 
Enrollment Date Post-Enrollment Hospital 
Visits  
Hospital visit charges for 12 
months before individual 
enrollment date  
Historical Control Group 
May 2017 – February 2018 
Hospital visit charges for 12 
months post to individual 
enrollment date 
Hospital visit charges for 12 
months before individual 
enrollment date 
Study Group 
March 2018 – July 2019 
Hospital visit charges for 12 
months post to individual 
enrollment date 
 
Because the OSOP peer recovery specialist provides patients with connection to 




hypothesized that this may potentially reduce the associated visit charges of patients in 
the post-period for the study group. To understand this phenomenon, a two-sample t-
test to determine the difference in means between the average charge of an opioid-
related hospital visit in the post-enrollment periods of the historical control and study 
groups was conducted. 
The second part of this analysis included quantifying avoidable utilization to 
determine the overall numerical value of cost avoidance to the health care system. As 
outlined earlier, avoidable utilization prevents the need for resource consumption and 
other related expenses to be incurred by the healthcare system. Health system cost 
avoidance was calculated by reviewing the gross charges of patients specific to the 
opioid-related emergency department visits and observation and inpatient admissions at 
any hospital within the state of Maryland. Total gross charges were then aggregated for 
the historical control and study groups for pre and post-enrollment opioid-related and 
non-opioid-related hospital visits. To account for the change in the value of gross 
charges throughout the study, the annual update factor issued by the Maryland Health 
Services Cost Review Commission (HSCRC) was applied. For example, any visit in the 
study that occurred in fiscal year (FY) 2020 was considered the base year. Charges 
associated with visits occurring before FY20 were reduced by 1.83%, the update factor 
provided by the rate-setting commission for FY19. Charges associated with visits 
occurring before FY19 were reduced by 3.14%; before FY18 were reduced by 2.16%; 
and FY17 were reduced by 2.40% (“Annual Update to Unit Rates…, 2020).   
Once a total for the value of aggregate cost avoidance related to hospital 




administering the OSOP program to calculate an overall net cost avoidance to the 
healthcare system. The operational costs of the OSOP program were calculated to be 
inclusive of salaries, fringe benefits, equipment (e.g. computer/laptop), office supplies, 
and associated mileage expenses for travel within the community. The value of cost 
avoidance from unnecessary spending and patient utilization was then compared with 
the cost to operate the OSOP program to determine its total benefit (value) to the health 
system. 
Results 
Characteristics of the study population (n=416) are included in Table 3. Among 
those that were included in the study group were 39.66% Black, Other, or Unknown and 
60.34% White. Those in the study population ranged in age from 18 to 83. The mean 
age of participants was 44.43. Of those in the study group, 25.96% were 18-34 years 
old, 31.73% were 35 – 49 years old, 35.82% were 50-64 years old, and 6.49% were 
over the age of 65. Like the study group, the historical control group included 
participants that were 39.66% Black, Other, or Unknown and 60.34% White. Of those 
matched to the historical control group, 25.96% were 18-34 years old, 29.81% were 35 
– 49 years old, 33.17% were 50-64 years old, and 11.06% were over the age of 65. 
65.87%, of those in the study group were male.  
The payor source was also derived using CRISP. For the study population, 
9.29% of those enrolled were covered under commercial plans, 53.85% under Maryland 
Medicaid – Managed Care (MC) plans, 6.01% under Maryland Medicaid – Fee for 
Service (FFS) plan, 14.90% under Medicare FFS, 3.37% under Medicare MC, and 




409 participants in the study group and 412 in the historical control group. For the 
historical control group, 11.41% of those enrolled were covered under commercial 
plans, 54.81% under Maryland Medicaid – Managed Care (MC) plans, 7.45% under 
Maryland Medicaid – Fee for Service (FFS) plan, 18.03% under Medicare FFS, 2.16% 
under Medicare MC, and 5.05% were noted as self-pay / charity care. The only 
significant differences in demographics between the two groups were those in the 
category of age greater than 65 and those with self -pay insurance. 
Table 3: Patient Characteristics: OSOP Peer Recovery Specialist Study Group and 
Historical Control Group 






Race/Ethnicity    
White 251 (60.34%) 251 (60.34%) 1.00 
Black / Other / 
Unknown 
165 (39.66%) 165 (39.66%) 1.00 
Age    
18-34 years 108 (25.96%) 108 (25.96%) 1.00 
35-49 years 132 (31.73%) 124 (29.81%) 0.55 
50-64 years 149 (35.82%) 138 (33.17%) 0.42 
65+ years 27 (6.49%) 46 (11.06%) 0.02* 
Gender    
Male 274 (65.87%) 274 (65.87%) 1.00 
Female 142 (34.12%) 142 (34.12%) 1.00 
Payor Source (n=409) (n=412)  
Commercial Other 38 (9.29%) 47 (11.41%) 0.30 
MD Medicaid – 
Managed Care 
224 (53.85%) 228 (54.81%) 0.78 
MD Medicaid – FFS 25 (6.01%) 31 (7.45%) 0.40 
Medicare – FFS  62 (14.90%) 75 (18.03%) 0.22 
Medicare – MC 14 (3.37%) 9 (2.16%) 0.29 
Self-Pay / Charity 46 (11.06%) 21 (5.05%) 0.001* 
*p < 0.05 
The analysis focused on the differences in the charges associated with opioid-




results. When collectively analyzing all visits for both the historical and study groups, the 
average charge of an opioid-related hospital visit, including emergency department, 
observation, and inpatient admissions, was $703 more than the average charge of a 
non-opioid related hospital visit. The average charge of an opioid-related hospital visit 
was $4,227.39 compared to $3,524.16 for non-opioid-related visits, a 16.6% difference. 
This difference was found to be statistically significant (t = -2.70; p = 0.0069). 
Table 4: Historical Control Group and Study Group Average Charge Per Hospital 
Visit Combined with Confidence Intervals 




Visits 1,980 $4,227.39 ($3,828.45, $4,626.33) 
Non-Opioid Related 
Visits 5,598 $3,524.16 ($3,255.79, $3792.53) 
Total Visit and 
Overall Aggregate 
Charge 
7,578 $3,707.90 ($3,483.86, $3,931.95) 
Difference 





 Further, when comparing opioid-visits in the post-enrollment period for the 
historical control and study groups, the average charge per visit in the study group was 
observed to be lower by $893. Table 5 denotes that the average charge per hospital 
visits for opioid-related events in the post-period for the study group was $4,035.40 
compared to $4,929.26 for the historical control group, a 18.1% reduction. This 
difference was not found to be statistically significant. (t= 1.445; p = 0.1488). As noted in 
Chapter 1, there were fewer opioid-related visits in the post-enrollment period for the 




Table 5: Average Charge per Opioid-Related Hospital Visits for Historical Control 
and Study Groups Post-Enrollment with Confidence Intervals 




Visits – Historical 
Control Group 
587 $4,929.26 ($4,044.13, $5,814.39) 
Opioid-Related 
Visits – Study 
Group 
445 $4,035.40 ($3,270.53, $4,800.27) 
Total – Combined 1,032 $4,543.83 ($3,942.27, $5,145.38) 
Difference - $893.85 (-$320.17, $2,107.88) 
 
Table 6 below provides a summary of the aggregate hospital visit charges for 
opioid and non-opioid related visits pre and post-enrollment periods for both the 
historical control and study group over a twelve-month period. The results demonstrate 
an impact of the OSOP intervention on cost avoidance to the healthcare system when 
compared to the historical control group for opioid-related visits. When comparing the 
pre and post-enrollment of those in the study group, the reduction in opioid-related visits 
resulted in a decrease of $145,801 in charges. However, the historical control group 
experienced the exact opposite results. When comparing pre and post-enrollment of the 
historical control group, the increase in overall opioid-related hospital visits resulted in 
the health system incurring $1,154,032 in charges. The best estimate of total charges 
avoided by the health system for opioid-related visits as a result of implementing the 







Table 6: Total Charges for Opioid and Non-Opioid Related Hospital Visits Pre and 
Post Enrollment for Historical Control and Study Group (12 Months) 
Historical Control Group 
N=416; Enrollment Period: May 2017-February 2018 


































































Similarly, when combining non-opioid and opioid-related hospital visits, the study 
group yields different results. When combining non-opioid and opioid-related hospital 
visit costs, the study group incurs $606,639 in charges. When combining non-opioid and 
opioid-related hospital visit costs, the historical control group incurs $1,577,640. Opioid-
related visit costs made up 73% of the total costs incurred in the historical control group. 




the health care system through the implementation of OSOP is $971,001 ($1,577,640 
increase in the historical control group less $606,639 in the study group). The overall 
operational costs of the OSOP program during the study period totaled $197,678. Table 
7 shows the total budget for the costs to facilitate the program for the four study 
hospitals included in this research.  
Table 7: Operational Costs of OSOP from Study Setting Hospitals 
Budget Item Amount 
Salaries (3.0 full-time) OSOP peer 
recovery specialists) 
$106,080 
Fringe Benefits (@ 23%) $24,398 
Supplies and Equipment (laptop, 
phone, materials, educational items, 
etc.) 
$34,650 
Other Expenses (mileage, 





If you incorporate the operational costs of OSOP, the best estimate of total 
hospital charges avoided by the health system through the implementation of OSOP for 
opioid-related hospital visits net of the program’s operational costs is approximately 
$1,102,155 ($1,299,833 of opioid-related hospital charges less the $197,678 in OSOP 
program costs). The net best estimate of total hospital charges avoided for all-cause 
hospital visits is approximately $773,323 ($971,001 of all-cause hospital charges less 
the $197,678 in OSOP program costs). These figures represent a summary of a net 
benefit analysis of implementing the program, and therefore, avoiding unnecessary 






Discussion of Results  
The results indicate that the implementation of OSOP results in a reduction of 
hospital charges of $1,102,155 for opioid-related hospital visits. The results also show a 
reduction in avoiding hospital charges when combining opioid and non-opioid related 
hospital visit costs. Hospital charges avoided for all-cause hospital visits totaled 
$773,323. In a total cost of care model, where the incentive is to reduce potentially 
avoidable utilization and the associated charges, the reduction in charges observed 
represents a cost-avoidance to the health system and a saving to the overall national 
healthcare expenditure. These findings demonstrate that OSOP may be effective in 
referring or linking patients to other medical services outside of substance use 
treatment. For example, OSOP may be effective in linking patients to primary care, or 
infectious disease services for those that may present complications or other medical 
concerns stemming from the use of substances. Additional analysis data would be 
needed to document and understand this phenomenon.  
The findings also suggest an incentive exists for hospitals to address opioid-
related events for patients because of statistically significant difference in the cost per 
visit compared to non-opioid related visits. The results showed that opioid-related 
hospital visits on average generate $703 more in associated hospital charges. Although 
not determined to be statistically significant, another finding of this study is that the 
costs for opioid-related visits for those in the study group after enrolling in OSOP were 
lower by $893 than patients with opioid-related in the historical control group. It is 
recognized that differences in associated visit charges for opioid-related visits between 




of associated visit charges for opioid-related events if there were differences in the 
insurance type between the historical control and study groups. However, the insurance 
type between patients in both groups was very similar. See Table 2 earlier in the 
chapter as a reference. Other reasons for this observed difference could be that the 
acuity of visits for those in the OSOP program was lessened by the resources provided 
to the patient as a participant in the program. These resources include naloxone, 
fentanyl-test strips, or connection to medication treatment modalities such as 
buprenorphine, methadone, or naltrexone. More data collection is needed to understand 
what might have led to the observed differences. 
Strengths and Limitations 
As mentioned in Chapter 1, one of the strengths of this study was that the 
regional information exchange system, CRISP, was leveraged to capture hospital 
utilization, charges, and insurance type. The use of this data allowed the analysis to 
capture a more comprehensive review of the OSOP program by incorporate hospital 
visit information beyond only MedStar hospitals. However, there are some limitations to 
using CRISP data in this analysis. As discussed in Chapter 1, as it pertains to analyzing 
patient utilization and cost data, that information is dependent upon the accuracy of 
provider documentation and ICD-10 coding. Both sources of data used for this analysis 
– MedStar Health’s electronic medical record and CRISP – provided patient utilization 
data with diagnostic codes that were used to determine whether a visit was opioid-
related or non-opioid related. The accuracy of coding data is not the sole concern. 
Information from CRISP only provided the first six diagnostic codes for a unique patient 




for inclusion in this analysis. If opioid-related codes were not among the top six in a 
patient’s record for a visit, that patient’s visit would be classified as a non-opioid related 
visit. 
The other limitations and strengths of this study are consistent with the themes 
discussed in Chapter 1. For limitations, this cost analysis was completed using data 
from the historical control and study groups that included a quasi-experimental study 
design and not a randomized control trial. Further, the analysis was completed by not 
knowing how the rapid increase in availability and use of fentanyl impacted hospital 
visits, as well as associated hospital charges. The impact of the coronavirus disease 
2019 (COVID-19) pandemic may have influenced patient utilization patterns. The 
strengths include the external validity of the historical control and study groups being a 
close reflection of opioid overdose deaths in the state of Maryland as it pertains to their 
demographics of gender, age, and race/ethnicity. 
Future Research 
The results of this study only include an analysis of the savings derived from 
acute care utilization. Therefore, the analyzed results are not reflective of a patient’s 
total cost of care. One of the goals of OSOP is to connect patients to healthcare 
services outside of the hospital that are proven to be less costly. If a patient enrolls in 
OSOP and gets connected to an outpatient treatment therapy such as buprenorphine to 
manage their opioid use disorder, the costs of those services were not included as part 
of this study. Future studies could follow the longevity of healthcare services accessed 
by patients through OSOP to get a more comprehensive view of the total cost of their 




As mentioned in the previous chapter, this study also was limited to assessing 
cost avoidance over a 12-month pre and post period for the historical control and study 
groups. Additional research could examine the longer-term impact of cost avoidance. 
For example, the aggregate value of cost avoidance may decrease in subsequent years 
as some members included in the study design experience to relapse, resulting in 
additional hospital visits and associated costs. This analysis could be paired with a 
broader view of not only assessing changes in hospital charges but narrowing the scope 
further to the actual unit-level cost of care delivered by the healthcare system. This 
analysis would include applying cost-to-charge ratio for each hospital visit. The cost-to-
charge ratio is a mechanism for determining the actual cost of hospital care when 
comparing what was charged to the patient and their respective health insurance plan. 
The cost-to-charge ratio varies by each specific hospital entity based upon the mix of 
services (e.g. tertiary services such as transplant procedures) (“Outlier Payments,” 
2013).  
Conclusion 
This result of this study suggests that the OSOP peer recovery specialist, which 
provides several supportive services and resources to patients – the connection of 
shared lived experiences, referrals to treatment programs, naloxone, education on 
opioid-use – is effective in not only reducing opioid-related and all-cause hospital visits 
but is an effective cost-avoidance strategy for the hospital or healthcare system. The 
OSOP peer recovery specialists support patients to receive care and treatment outside 
of the hospital in outpatient environments, which in turn is a more cost-effective means 




providing an incentive for broader application in other hospital settings and encourage 
dialogue on the potential for peers to be reimbursed in Maryland for their services so 
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Figure 1: Screening, Brief Intervention, and Referral to Treatment Components 



















Chapter 3: Engaging Opioid Overdose Survivors: Insights from the Field on the 
Role and Efficacy of Peer Recovery Specialists 
Abstract 
 The previous two chapters evaluated a health system’s implementation of a peer 
recovery specialist intervention known as Opioid Survivor Outreach Program (OSOP). 
Chapters 1 and 2 demonstrated a favorable impact on achieving reductions in 
subsequent hospital utilization for opioid-related events, and therefore, reduced 
associated hospital charges. This study sought to interview the frontline peer recovery 
specialists, as well as emergency department physicians and nurses to provide a 
comprehensive evaluation of the efficacy of the program. A total of 11 individuals in 
these roles participated in in-depth interviews. Interviews included three key areas of 
questions – effective strategies to engage patients in OSOP, best practices to refer and 
link patients to treatment, and gaining insights of the OSOP peer recovery specialist as 
a member of the multidisciplinary healthcare team. Interviews from participants 
confirmed that a peer recovery specialist lived experiences encourage patients to 
engage in the program. Peers also have a command of the treatment ecosystem to 
effectively advocate and link patients to care. Further, insights from providers give other 
health institutions considerations on how to build a successful OSOP program in the 








Introduction and Statement of the Problem 
 Opioid-related deaths in the state of Maryland increased by an alarming 300% 
between 2010 and 2018. As outlined in the previous two chapters, states and local 
jurisdictions have sought to develop and deploy a variety of strategies to address the 
nation’s opioid epidemic. These interventions are often multi-faceted given the 
complexity of the crisis. Specific interventions within these areas included expanding 
access to medication therapy treatment, monitoring and placing limitations on providers 
to prescribe opioids, increasing the availability of naloxone, and creating drug courts to 
support rehabilitation over criminalization (“Executive fOrder…,” 2017; “Missouri 
Department of Public Safety,” 2017). States have also found that nonfatal overdoses 
are a strong risk factor for fatal overdose events. In 2013, Maryland found that 66% of 
individuals that died from an opioid overdose had at least one hospital visit before their 
death (Holler, 2016). Knowing this risk factor, states have also used federal and state 
funding to develop hospital-based programs that seek to engage individuals with 
substance use disorders. 
  One of those strategies is to integrate peer recovery specialists, those with lived 
experience with substance use in their past, into emergency department environments. 
Many states, including New Jersey, Nevada, and Indiana have deployed peer recovery 
specialists within hospital environments to connect with patients at-risk for overdose. 
These programs work directly in and/or with emergency department providers to 
connect patients to treatment and provide them with naloxone administration training 
(McGuire et. al., 2020). The purpose of this research is to evaluate the effectiveness of 




state, MedStar Health was one of the first hospital systems in Maryland in partnership 
with the state Department of Health and Mosaic Group to implement the Opioid Survivor 
Outreach Program (OSOP). Driven by a peer recovery specialist with lived experience 
specific to opioid use in their past, the tenets of the intervention are to connect with 
patients in hospital environments that experience opioid overdoses. The program 
provides patients with several supportive services and resources – the connection of 
shared lived experiences, referrals to treatment programs, naloxone, and education on 
opioid use. 
The first two chapters demonstrate that OSOP supports reducing subsequent 
opioid-related and all-cause hospital visits after enrollment, even when compared to a 
historical control group. These findings support the ability to reduce unnecessary 
hospital utilization and provide an effective means of cost avoidance by the healthcare 
system. While the literature is vast in its depth of qualitative research on the efficacy of 
peer recovery specialists in the mental health and substance use arena, the goal of this 
research is to learn more about the efficacy of the OSOP program in achieving the 
reductions in hospital utilization and cost avoidance. Building upon the quantitative data 
analyzed, qualitative methods will be applied in structuring, conducting, and analyzing 
the results of interviews with OSOP peer recovery specialists, emergency department 
nurses, and emergency department physicians. The insights gained will assist in a 
comprehensive evaluation of OSOP using not only quantitative data analyzed in the 
previous two chapters, but also qualitative data. The intention of collecting qualitative 




to implement the same or similar peer-driven intervention. Specifically, the aims of this 
research through interviews with frontline staff are to glean the following:  
• Summarize effective strategies used in the OSOP intervention to avoid future 
acute hospital utilization  
• Review and determine best practices in referring and linking patients to 
substance use treatment to prevent future inpatient utilization 
• Understand the OSOP peer recovery specialist’s relationship as a member of the 
healthcare system and an integrated member of the interdisciplinary healthcare 
workforce 
• Document any barriers or improvements that could be made to strengthen the 
program as it is considered for broader implementation at other hospital systems 
Literature Review 
The United States Substance Abuse and Mental Health Services Administration 
(SAMHSA) defines peer providers as “a person who uses his or her lived experience of 
recovery from mental illness and/or addiction, plus skills learned in formal training, to 
deliver services in behavioral health settings to promote mind-body recovery and 
resilience (“Peer Providers,” n.d.)”. Peer recovery specialists have gained traction as 
advocacy, self-help organizations, and twelve-step-based programs began to rise with 
more prominence (Myrick and Vecchio, 2016). One of the first programs, Alcohol 
Anonymous, began in the late 1930s. Throughout the past century, other groups have 
been created that model the organization’s approach, inc luding Narcotics Anonymous 




Substance Use Treatment,” 1999). The integration of peers into these programs started 
to first occur in the 1970s (Myrick and Vecchio, 2016). 
The use of peer recovery specialists has demonstrated significant and 
compelling outcomes for clients and patients served. Favorable clinical outcomes 
include assisting patients in recovery by increasing the days of abstinence and 
providing measurable decreases in substance use (Rowe et. al., 2007). Peers also add 
value in providing several psychosocial support and connection to services for patients, 
including housing (Boisvert, Martin, Grosek, and Clarie, 2008), reducing criminal activity 
(Rowe et. al., 2007), and encouraging primary care treatment and goals of care 
adherence (Tracy, Burton, Nich, and Rounsaville, 2011). It is also worth noting that the 
role of a peer recovery specialist is replicated to support other patients, such as those 
with chronic disease. Roles such as community health workers or lay health advisors 
have also shown similar results for these chronic disease states. The Witness Project, 
which is focused on providing health education, specifically targeting black women, 
reported an increase in the rate of breast and cervical cancer screenings using lay 
health advisors (Shelton et. al., 2015). 
The first two research aims were designed to review the OSOP peer recovery 
specialist program from an effectiveness perspective on reducing patient utilization and 
cost. However, the opportunity to conduct qualitative in-depth interviews allows for a 
more comprehensive analysis of the program. Specifically, in-depth interviews allow for 
a deeper analysis of what exactly allows the OSOP peer recovery specialist to be so 
effective. Qualitative research has been conducted to understand the efficacy of the 




their integration into the state mental health system, peers, their supervisors, and clients 
were interviewed. Peers, supervisors, and clients all noted that their effectiveness lies in 
their ability to connect and build rapport through a mutually shared experience. This 
research was conducted just after the Affordable Care Act started covering more 
behavioral health services through health plans, and therefore, encouraged more 
widespread peer adoption in a variety of healthcare settings. The gaps identified in the 
literature were opportunities to further define the role of a peer recovery specialist in 
terms of expectations in integrating peers as part of a multi-disciplinary healthcare team 
(Cabral et. al., 2013). 
Other studies have sought to examine the implementation of peer recovery 
specialist programs funded by the 21st Century Cares Act through qualitative data. 
Assessing peer recovery specialist support specific to opioid use that was integrated 
into a women’s health clinic in Kentucky found the following emerging themes of what 
makes an effective peer in the view of patients – lived experiences, authenticity, and are 
an accountability partner to maintain participation in treatment programs. The outcomes 
noted positive results in assisting women in their treatment and continuum of care, 
especially post-partum (Fallin-Bennett, Elswick, and Ashford, 2020). A review of 
emergency-based peer programs in three states – New Jersey, Nevada, and Indiana – 
by McGuire et. al (2020) had the same goals as the Opioid Survivor Outreach Program, 
the intervention central to this research. Specifically, the programs were designed to 1) 
integrate peer recovery specialists as part of a multidisciplinary healthcare team in the 
emergency department, 2) focus efforts on identifying opioid overdose survivors and 




support services. Given that not much is known on patient outcomes, or assessment of 
health system outcomes, such as patient utilization or cost avoidance, the researchers 
suggested that future studies should look to evaluate these elements to encourage 
more widespread adoption in other acute, or outpatient clinical settings (McGuire et al., 
2020). 
The OSOP peer recovery specialist program as the primary focus of this 
research proved successful in reducing subsequent hospital visits after enrollment in the 
program. However, this research seeks to explain those findings in a qualitative 
research design by interviewing the OSOP peers, as well as the physicians and nurses 
that interact with the program to care for patients. Specifically, the purpose of this study 
was to assess three areas – effective strategies used to enroll patients in OSOP, best 
practices in referring and linking patients to substance use treatment, and 
understanding the OSOP peer recovery specialists’ relationship as a member of the 
larger interdisciplinary healthcare workforce. Such findings should assist in 
recommending program adoption to other healthcare systems. 
Methods 
Design 
Informed in partnership with the Maryland Department of Health and the Mosaic 
Group, a community health services national consulting firm, the OSOP peer recovery 
specialist conducts a multi-pronged effort as part of the intervention, which on average 
is a 30-90-day engagement period with each enrolled patient. Patients are connected to 
the program through a few different methods. Individuals can be referred to the program 




as a reason for visit, or if a patient self-reports opioid use as part of their emergency 
department visit. The OSOP peer recovery specialist provides a range of supportive 
services to patients, including, but not limited to referring and linking patients to 
treatment, supportive services such as access to housing, transportation, and food 
resources, and providing harm reduction tools (e.g. naloxone) or education.  
Implementation at MedStar Health was first launched in the Baltimore regional 
hospitals in March 2018. The hospitals included MedStar Harbor Hospital, MedStar 
Good Samaritan Hospital, MedStar Union Memorial Hospital, and MedStar Franklin 
Square Medical Center. The OSOP program is an extension of existing peer recovery 
specialist programs at the four hospitals that have been in place since 2017. MedStar 
Harbor Hospital and MedStar Franklin Square Medical Center employ one OSOP peer 
recovery specialist for their respective campuses. Given the overlapping service areas, 
MedStar Union Memorial Hospital and MedStar Good Samaritan Hospital share an 
OSOP peer recovery specialist between their two campuses. Therefore, three OSOP 
peer recovery specialists cover all four hospitals. Through the period of March 2018 – 
July 2019, the OSOP peer recovery specialists have worked with 615 patients. In this 
study, the first two research aims were analyzed to find a directional reduction in opioid-
related visits and associated costs over a 12-month period. Data were then collected by 
conducting in-depth interviews with three key stakeholders of OSOP – OSOP peer 
recovery specialists, emergency department physicians, and emergency department 
nurses. The study was approved by the MedStar Health Research Institute and Johns 




A total of four (4) OSOP peer recovery specialists were asked to participate in 
the study, and two accepted the invitation and completed the interview. One of the 
OSOP peer recovery specialists that participated in the interview is a peer assigned to 
one of the study setting hospitals. The other OSOP peer that completed an interview is 
assigned to a hospital within the MedStar Health system, but not at one of the study 
setting hospitals. Other MedStar Health hospitals have implemented OSOP since the 
four included in this study, and to increase the number of eligible OSOP peer recovery 
specialists to participate in interviews, OSOP peers from other hospital settings were 
included as part of the recruitment process. It is important to note that the OSOP peer 
recovery specialist that participated and is not directly employed at one of the study 
setting hospitals received the same training as the other OSOP peer. Additionally, the 
OSOP programs at the other MedStar Health hospitals have the same policies and 
protocols for operations, including identification of patients, referral criteria, and data 
collection/evaluation. 
 The physicians selected to recruit for the interviews were those that serve in a 
leadership capacity as either chair or vice-chair of the emergency department, but also 
practice clinically at the study setting hospitals. A total of eight physicians were asked to 
participate in the study, and five accepted the invitation and completed the interview. 
The nurses selected to recruit for the interview were those that serve in a charge nurse 
capacity of the study setting hospitals. A total of 25 nurses were asked to participate in 
the study, and four accepted the invitation and completed the interview. All those 
recruited to participate received three follow-up e-mails, as well as a phone call. The 




interview did not refuse to participate; rather, these individuals did not respond to any 
contact attempts. Interviews with physicians and nurses lasted between 12 to 46 
minutes with the average length running approximately 32 minutes. Both interviews with 
the OSOP peer recovery specialists were over 1 hour.  
Interviews were conducted by two masters-level students at the Johns Hopkins 
Bloomberg School of Public Health. Both students completed ethical research training 
through the Johns Hopkins Bloomberg School of Public Health and participated in two 
mock interviews with Ryan Moran, the lead researcher of the study before completing 
any official interviews. Participants in the interviews were recruited to participate in a 
secure WebEx video conferencing service. Interviews were not conducted face-to-face 
due to the COVID-19 global pandemic. Interviews were recorded via the WebEx 
platform. Interviews were then transcribed by Ryan Moran, the lead researcher of this 
study. Interviews included open-ended, scripted questions that were informed by other 
qualitative research previously conducted in this field, such as the work of Powell et al. 
(2019) to evaluate peer recovery specialist programs in the state of New Jersey. The 
qualitative data from the interviews were designed to evaluate and help discern and 
explain the results as it relates to changes in inpatient utilization and its potential 
corresponding impact on reducing unnecessary hospital costs. The interviews served to 
also help shape best practices to be shared for other programs, hospitals, or health 
institutions wishing to design a successful implementation of OSOP. The full key 
informant guide used by the interviewers, as well as the questions for all three 
stakeholders can be found in Appendix: Figure 1. The structure of the interview 




• Effective strategies used in the process to avoid future acute hospital utilization  
• Best practices in referring and linking patients to substance use treatment to 
prevent future inpatient utilization 
• Insights on their relationship with the healthcare system as an integrated member 
of the interdisciplinary healthcare workforce 
Analysis 
After transcription of all interviews, the data were analyzed and coded by Ryan 
Moran, the lead researcher on this study to appropriately capture and articulate key 
themes. Specifically, the analytical method of narrative content analysis was used to 
interpret the responses and identify patterns from the research (Owczarzak, 2020). The 
analysis used a mix of both inductive and deductive techniques. The process was 
deductive because specific categories that framed the interviews and corresponding 
responses were gleaned from previous studies. For this research, those categorical 
selections – effective strategies to engage patients, best practices in linking and/or 
referring patients to treatment, and collecting insights on peer recovery specialists as 
part of the health care team – were derived from previous qualitative review of peer 
recovery specialist programs in New Jersey (Powell et al., 2019). The process was 
inductive as the content of interviewee responses allowed for additional codes, 
categories, or themes to emerge (Owczarzak, 2020).  
The analytical technique also followed a latent analysis when reviewing the data, 
which allows codes, themes, and categories to be derived by evaluating the intention or 
meaning of the participant responses (Bengtsson, 2016). The process of reviewing the 




included the four steps of the content analytical process – decontextualization, 
recontextualization, categorization, and compilation of research for analysis. The full 
framework for analysis is included in Appendix: Figure 2. Additional recruitment was 
not completed after the coding of the first 11 interviews as the researcher determined 
that responses provided reached a level of saturation. Saturation in the analysis is 
defined as the point within the research where no new insights, categories, or emerging 
themes can be gleaned from additional data collection. Previous literature that assesses 
the most appropriate number of in-depth interviews in public health research suggests 
that saturation occurs in the first twelve interviews conducted (Guest, Bunce, & 
Johnson, 2006). 
Results 
 A total of 11 interviews were completed – two OSOP peer recovery specialists, 
five emergency department physicians, and four emergency department nurses. 
Participating nurses and physicians all had significant tenure with the organization. 
Their experience practicing emergency department nursing or physician practice ranged 
between 3 and 16 years at the study setting hospitals. This tenure allowed them to 
contextualize responses from a perspective of working in the emergency department 
before OSOP implementation. The OSOP peer recovery specialists participating in this 
study included an individual that was hired at program inception while the other peer 
had less than one year of experience in the role.  
The results below are organized as it pertains to the research study’s three key 
areas of interest – determining effective strategies used to engage patient in OSOP 




OSOP peer recovery specialists’ relationship as a member of the healthcare team . 
Because of the sample size, information, or direct quotes that may be linked to 
personally identifiable information have been removed or edited, from any responses 
included in the results.  
Effective Strategies to Engage Patients in OSOP 
 Responses from physicians and nurses report that the chief reason that OSOP 
peer recovery specialists are so effective in convincing patients to engage in the 
program is their ability to relate. They stressed their efficacy of being a peer to patients, 
bringing their own lived substance use experiences to their work. This allows them to 
relate to patients and establish trust in a way that clinical providers are not able to 
harness. Analysis of participant responses validated that the OSOP peer recovery 
specialists were effective in their role – from patient engagement to referring and linking 
patients to treatment – because of their ability to relate with patients in a way that is 
different from clinical providers. In engaging patients to talk about enrolling in the OSOP 
program, one nurse illustrated the power of a shared connection between the patient 
and peer recovery specialists: 
Provider: “We like to reiterate that these are people [OSOP peer recovery 
specialists] that are their peers, that have been where they have been…It's easy 
for us as hospital staff to lecture them or give them [patient(s)] information, but 
without us ever being in their shoes, being where they are…we just like to relate 
those two things together to make the individuals more susceptible to speak with 




 Similarly, another key theme that emerged from nurses and physicians is the 
importance of integrating the peer recovery specialist early in the patient’s emergency 
department visit, regardless of whether their chief complaint was related to substance 
use. This allows the peer to devote more of their time in working with the patient to 
understand their readiness for support to enroll in OSOP. Providers and peers also 
provided insight as to why OSOP peer recovery specialists may not be effective in 
engaging patients to enroll in the program. The top reasons included individual patient 
readiness to seek support and/or treatment for their substance use disorder, as well as 
patients not acknowledging that their substance use disorder is a concern.  
Peer: “When they are ready, it’s easy. If they are not ready, it’s hard. Once 
again, you're talking about the disease of addiction, and a lot of times people 
don't know that they have a disease. They are in denial. When you are in denial, 
you don't know that you are in denial until you come out of denial. I understand 
the process. I’m a person myself in long-term recovery, so I understand the 
process. It is easy when they're ready, and it's very difficult when they are not.” 
For patients that declined to participate, one best practice noted was the peer 
recovery specialists would leave their business card with their contact information. They 
encourage patients to follow up if the patient changes their mind or wants to discuss 
peer services in the future. Other notable reasons included patients having enrolled 
previously in a treatment program and found that to be unsuccessful, or some 
presenting with substance use were already engaged in a treatment program (e.g. 
medication therapy program, residential program, etc.). 




Providers shared their impressions that peer recovery specialists have a superior 
knowledge of the treatment provider system, as well as the ability to advocate on their 
behalf to receive these services.  
Provider: “I think that a lot of the peer recovery coaches have ins or ties to 
certain places. So, I think that they are much more effective at getting people to 
these facilities than I might be, or even knowing what all of them are. Unless we 
do our own digging or research I just feel like, they know much more about the 
whole process than we do and what the patient needs to get there, or get in.” 
These providers also acknowledged that providing a patient with supportive 
services is also an effective means to capture the opportunity on a patient’s readiness 
for care. Thus, the practice of arranging transportation directly from the emergency 
department to an agreed-upon treatment provider assists in the accountability of 
patients to commit to receiving treatment. Other commonalities of best practices of 
navigating patients to care included working with emergency department physicians to 
ensure patients had appropriate medications and/or prescriptions to enroll in outpatient 
programs. Peers noted how important it was to link their patients to treatment services. 
Peer: “Very. That's right at the top of the list. Top of the list. It’s urgent. It’s 
urgent.” 
Peer: “I want to say a seven out of ten, because yes, I want to see them to get 
help. I want to see them turn things around, but sometimes it’s going to take 
three months before they're willing to do that. Yeah, it's about the relationship 




emergency department. It upsets me, but there’s still more opportunities. I don’t 
see it as a failure because now I'm still going to be in contact with them.” 
 In this series of questions, all 11 participants were provided with preliminary 
results of the study’s research aims on patient utilization and cost. The program’s 
impact on reducing opioid-related hospital visits, as well as assisting the health system 
in avoiding cost was all met with favorable reactions. Half of the participants noted that 
they would have expected to see even more favorable results as it pertains to patient 
recidivism to the emergency department. This finding corresponds with providers’ 
reactions to the positive experiences and outcomes in working with peer recovery 
specialists. They believe that the impact that peer recovery specialists have in referring 
or linking patients to substance use treatment to reduce future hospital visits is greater 
than what is observed in the raw data. Thus, their perception is that peer recovery 
specialists are supporting patients’ needs in a significant way to reduce future opioid-
related hospital visits. 
 While understanding best practices for referral and linkage to substance use 
treatment is useful, this research also provided evidence for the barriers that peer 
recovery specialists also encounter. The chief barrier among all participants interviewed 
is the availability or accessibility of finding patients’ treatment options. The participants 
illustrate the challenges of finding the appropriate level of behavioral health service to 
meet patient needs based on a variety of factors – acuity level, treatment provider hours 
of operations, insurance accepted, and the mere lack of treatment options. A provider 




Provider: “I'm guessing there's probably a limited number of places they can go 
for recovery and so they have a limited number of beds and staff to care for 
these patients. That’s probably the biggest barrier having enough centers or 
detox centers for the patients.” 
One of the peers noted the difficulty of treatment access based on insurance 
accepted by the treatment program. 
Peer: “Some places just won't accept it [patient’s insurance]. A lot of patients 
have Medicaid. There are only two providers that take Medicaid, or maybe one. If 
they don’t have the supplement of A or B, then it’s a struggle. And then, with no 
insurance, we advocate with the social work team to get them some insurance so 
we can get them in the door.” 
The other barriers to serving patients were not only lack of access and availability 
of treatment providers, but the lack of resources from a societal perspective to support 
patients. The most common additional resources that can serve as a barrier to serving 
patients and their substance use needs include access to reliable transportation, as well 
as quality and affordable housing. One provider discussed both challenges to serve 
patients, narrating the intersection of social determinants of health and clinical services.  
Provider: “I don’t know how we could provide this, but stable housing. And if 
there's some way to assist in that regard…stable housing is in the root of a lot of 
people's problems. Again, transportation is also an issue, if there's some way 
they can help with that.” 
Other solutions and ideas were also provided to strengthen OSOP intervention 




most common barrier of treatment availability and accessibility, participants called for 
more mental and behavioral crisis investments by the hospital. Further, other common 
themes included the development of a more proactive community-based model for peer 
recovery specialists. Participants noted the program integrated with the hospital as 
reactive, meaning that patients must present with an overdose or opioid-related event 
before being able to get support. They suggested a model where community navigation 
of a peer recovery specialist team could be deployed in communities that would support 
the goal of saving even more lives. Further, other ideas also included providing more 
naloxone and medication assistance for patients that may not be able to afford opioid 
treatment medications. 
OSOP Peer Recovery Specialist Relationship as Member of Healthcare Workforce 
 The overwhelming response from nurses and physicians provided in this 
research commented that the overall experience of working with the OSOP peer 
recovery specialists has been positive or very positive. Eight of the nine individuals 
interviewed noted their experiences and interactions ranged from positive to very 
positive. Only one provider commented on having limited interaction in working with the 
peer recovery specialists. Of most significance, the OSOP peer recovery specialists as 
an integrated team member in the busy emergency department environment were 
deemed to enhance or assist their practice as a clinician. One physician explicitly noted:  
Provider: “It clearly doesn't detract [from our clinical practice] at all. Ever. 
Clearly, it's just as if it was another service that we feel we never thought about, 





To arrive at this state of collaboration, participants noted that the implementation 
of OSOP did not come without its challenges or barriers. Participants noted that there 
was not always full buy-in from staff when the program began. 
Provider: “There was distrust on the staff at the beginning. We wondered who 
they [peers] were and if they would really find the resources for our patients. But 
watching them do it, having rapport with the patients and understand their role 
has changed staff perception.” 
 These providers commented on the evolving nature of the relationship between 
the peer recovery specialists as the program has matured and become part of standard 
clinical operations. Since its inception, the overall sentiment is that the peers have 
become more integrated with the department over-time. This evolution of a stronger 
relationship and integration as part of the healthcare team results in having buy-in from 
staff through proper training and education. The lack of buy-in from all staff – 
physicians, nurses, social work, and other providers – is noted as one of the key pitfalls 
to avoid if other hospitals are considering adopting the program. To facilitate this buy-in, 
participants suggested proper staff training to introduce the OSOP peer recovery 
specialist, as well as their role and responsibilities.  
Provider: “Explain to your staff what the peer recovery coach can provide and 
how they can help you is huge. Because sometimes the nurses or doctors may 
feel like it is a burden. Make sure that when you integrate the service that you 
introduce everyone to the peer, what their purpose is and what they are there for. 




 Nurses and physicians also provided practical considerations as other hospitals 
or hospitals consider adopting the OSOP program. They note the selling points of the 
program include the ability for organizations and healthcare providers to save lives, 
connect their work to the mission of their entities, and reduce emergency department 
recidivism and overall cost. They advised on resources needed to adopt the program 
including the ability to hire and manage the peer recovery specialist teams, ensure 
proper space in the department for peers to work, and having the ability to connect 
patients to the OSOP resources through electronic medical record (EMR) screening 
tools and referral processes.  
In summary, common and key themes from each of the three-research questions 
and areas for physician and nurse interviews are documented in Table 1. The below 
results are a summation of results provided through the study. A full codebook of all 
results is listed for reference in Appendix – Figure 3.  
Table 1: OSOP Peers, Physician, and Nurse Interviews: Common and Key Themes 
with Included Sample Quotes from Participants  
Research Area 1: Effective Strategies to Engage Patients in OSOP 




Notable Quotes from Participants or Code 
Explanation  
Positive Experience 10 Provider: And then as a resource nurse, it's kind of nice to have 
that extra person there to kind of look into things and maybe even 
offer a different perspective on our patients. So, it's been a good 
experience to interact with them. 
Collaborate on Patient 
Care 
5 Discusses how providers work with peers to connect patients to 
treatment. 
All: What are effective ways to engage patients in OSOP? 
Relatable to Patient  15 Provider: We like to reiterate that these are people [OSOP peer 
recovery specialists] that are their peers, that have been where 
they have been…It's easy for us as hospital staff to lecture them 
or give them [patient(s)] information, but without us ever being in 
their shoes, being where they are…We just like to relate those two 
things together to make the individuals more susceptible to speak 




Early Integration of 
Peer in Care  
6 Refers to integrating the peer early in the patient’s care to engage 
them in OSOP program. 
Patient 
willingness/readiness 
2 Refers to OSOP peers encountering patients at a stage for 
change. 
Contact Information  2 Leaving contact information behind if patient is not ready to enroll 
so that patient can enroll for future outreach 




Notable Quotes from Participants 
Readiness 10 Peer: When they are ready, it’s easy. If they are not ready, it’s 
hard. Once again, you're talking about the disease of addiction, 
and a lot of times people don't know that they have a disease. 
They are in denial. When you are denial, you don't know that you 
are in denial until you come out of denial. I understand the 
process. I’m a person myself in long-term recovery, so I 
understand the process. It is easy when they're ready, and it's 
very difficult when they are not. 
Acknowledgement 8 Patient recognizing that there is a substance use and/or misuse 
present. 
Already Engaged in 
Treatment 
2 Patient is already linked to existing treatment program 
Previous Negative 
Treatment Outcome 
2 Patient resists treatment option due to having a negative 
experience or outcome. 
Providers: Do you believe that OSOP enhances or distracts from your clinical 
practice? 
Easier 6 Provider: It clearly doesn't detract [from our clinical practice] at 
all. Ever. Clearly, it's just as if it was another service that we feel 
we never thought about, but also now, I can’t imagine how we can 
even practice ED medicine without having them. 
No More Difficult 5 Providers note that OSOP peers make it no more difficult to 
practice. 
Research Aim 2: Best Practices to Refer and Link Patients to Treatment 








13 Provider: I think that a lot of the peer recovery coaches have ins 
or ties to certain place. So, I think that they are much more 
effective of getting people to these facilities than I might be, or 
even knowing what all of them are. Unless we do our own digging 
or research I just feel like, they know much more about the whole 
process than we do and what the patient needs to get there, or get 
in. 
Transportation 6 Peers arranging transportation directly from emergency 
department to end payments to treatment programs/services 
Time 6 Refers to the amount of time peers must devote to patients that 
clinical providers do not. 
Advocacy 6 Working with ED providers to advocate for clinical care delivery in 
order to prepare treatment for program/outpatient placement 
All: Barriers to refer or link patients to treatment, 
Access and Availability 13 Provider: I'm guessing there's probably a limited number of 
places they can go for recovery and so they have a limited 
number of beds and staff to care for these patients. That’s 
probably the biggest barrier having enough centers or detox 





Peer: Some places just won't accept it [patient’s insurance]. A lot 
of patients have Medicaid. There are only two providers that take 
Medicaid, or maybe one. If they don’t have the supplement of A or 
B, then it’s a struggle. And then, with no insurance, we advocate 
with the social work team to get them some insurance so we can 
get them in the door. 
Transportation 3 Patients do not have reliable access to transportation to engage in 
a program. 
Peers: How important is it to you to get your patient into treatment? 
Important – Very 
Important 
2 Peer: Very. That's right at the top of the list. Top of the list. It’s 
urgent. It’s urgent. 
 
Peer: I want to say a seven out of ten, because yes, I want to see 
them get help. I want to see them turn things around, but 
sometimes it’s going to take three months before they're willing to 
do that. Yeah, it's about the relationship that you make. I’m not 
super depressed if they don’t get sent right from the ER. It upsets 
me, but there’s still more opportunities. I don’t see it as a failure 
because now I'm still going to be in contact with them. 
All: What more could be done to serve opioid overdose survivors? 
Mental Health/Crisis 
Services 
6 More behavioral health capacity in outpatient and inpatient 
settings are needed to serve population. 
Stable Housing 2 Provider: I don’t know how we could provide this, but stable 
housing. And if there's some way to assist in that regard…Stable 
housing is in the root of a lot of people's problems.  
Community Peer 
Model 
2 Participants note that peers embedded in the community may be a 
preventative model to consider. 
All: What are your initial reactions to seeing preliminary results of decreased visits 
and cost savings to hospital through patients engaging in OSOP? 
Amazing / Positive / 
Good 
8 Participants respond favorably to seeing utilization and cost data 
results. 
Not surprised / Neutral 3 Participants respond neutrally to seeing patient and cost data. 
All: Were the results as you would have expected? 
Less Than Expected 4 Participants respond that they thought that utilization and cost 
results would be more significant. 
Better Than Expected 3 Participants respond that they thought results were better than 
expected. 
As Expected 4 Participants respond that they thought results were as expected. 
Research Aim 3: OSOP as a Member of Healthcare Team 
All: How has the relationship changed between ED providers and OSOP peers since 




Notable Quotes from Participants 
More Integrated – 
Collaborative 
8 Participants observe a more integrated and collaborative model 
since first adoption. 
Communication 
Improved 
5 Participants observe better communication to serve patients 
between providers and peers. 
All: Resources needed for success – considerations for other health systems adopting 
Peers 6 Peers are needed to effectively make the program successful. 
Office Space 4 Peers and other staff need space in order to be integrated into the 
team. 




Staff Buy-In 2 Key to success is having buy-in from all staff that work with peers. 
MAT  2 Providers note that it is helpful to have initiation of MAT to support 
patient treatment options. 
Outpatient Treatment 
Access 
2 Outpatient treatment capacity is needed to effectively serve 
patients. 
Training – staff 2 Program must be supported by quality training. 
All: What are the selling points of the program? 
Mission-Driven 8 Program is at the heart of service in a health system and aligns 
with hospitals mission to serve communities  
Patient Recidivism and 
Cost 
6 Program helps reduce patient visits to hospital. 
All: What are the pitfalls to avoid? 
Staff Buy-in 5 Provider: Explain to your staff what the peer recovery coach can 
provide and how they can help you is huge. Because sometimes 
the nurses or doctors may feel like it is a burden. Make sure that 
when you integrate the service that you introduce everyone to the 
peer, what their purpose is and what they are there for. You want 
to make sure that relationship is well received from the beginning. 
 
Provider: There was distrust on the staff at the beginning. We 
wondered who they [peers] were and if they would really find the 
resources for our patients. But watching them do it, having rapport 
with the patients and understand their role has changed staff 
perception. 
Weak EMR / Process 3 Workflow and processes must be supported by hospital/site EMR. 
 
Discussion of Results  
 The rapid advent of the integration of peer recovery specialists into acute care 
settings to address the opioid epidemic is a trend realized nationwide through federal 
funds from the 21st Century Cures Act. The role of peer support to assist patients in the 
behavioral health field of medicine has demonstrated effective outcomes ranging from 
improved clinical outcomes, reduced mortality, and greater adherence to care plans 
(Boisvert, Martin, Grosek, and Clarie, 2008; Rowe et. al., 2007; Tracy, Burton, Nich, and 
Rounsaville, 2011). The leading national organization to issue these funds, SAMHSA, 
recently noted the role of peer support as a core element to the future of behavioral 
health care delivery (“Peer Support Recovery Is the Future,” 2020). Ohio 
Empowerment, a behavioral health advocacy and training organization, has equipped 




lead executive, Jack Cameron, provides a thoughtful summation of the results of this 
research:  
“The real value a peer supporter has is that they are uniquely qualified to engage 
people with mental health issues. When we look at what we call ‘hotspots’—
people who use a lot of health care services—early evidence indicates that peer 
supporters can reach people who are hard to reach. Sometimes, someone who 
has a similar history but who has developed the ability to stay out of the hospital 
has credibility, can get people to try things they might be reluctant to try. They 
engage the consumer, make a connection, do the little things. It is really an art 
form.” (Paragraph 10) 
 Chapters 1 and 2 of this research measured the efficacy of reducing hospital 
visits by enrolling high-risk, vulnerable opioid overdose survivors from emergency 
departments into a peer recovery specialist program. The results proved promising, 
demonstrating a reduction in subsequent hospital visits with associated avoidance of 
health care costs. This chapter sought to provide a more comprehensive review to 
glean insights on what makes the program successful in reducing hospital visits. This 
study suggests that the “art form” of a peer to connect with patients, engage them in 
their recovery, and advocate for them throughout the healthcare ecosystem are the 
elements to their efficacy. The findings validated other qualitative studies performed that 
suggest their lived experiences are a key element to relating to patients (Cabral et. al., 
2014). Participants also note that one of the most effective aspects of the program is the 
peer recovery specialists’ superior knowledge of the substance use treatment 




programs because of their strong and often long-standing relationships with community 
treatment providers. 
The study also adds new contextual evidence of peer recovery specialist 
integration into hospital emergency department settings by surveying nurses and 
physicians on how they work together to deliver patient care. The experiences in 
working with peer recovery specialists were unanimously positive with the illustration of 
the value that they provide to thinking of peers as a standard role in the delivery of 
emergency medicine. One provider even notes that “I’m not sure how we can even 
practice emergency medicine without them.” However, it is also important to note that 
this high appreciation of the peer recovery specialist role was not immediate. It took 
time in providing necessary staff training on the scope and parameter of their role, as 
well as observing the value that this role brings as an interdisciplinary member of the 
clinical care team. Participants site this as an internal cultural barrier that was overcome 
to make the program as successful and collaborative as it is today. 
 The program’s success and day-to-day operations were noted to also have 
challenges and barriers to effectively serve patients. The participants on the frontline of 
the opioid epidemic in urban and suburban study setting hospitals brought forth the 
validation of challenges in servicing this patient population. Namely, they cite lack of 
outpatient and inpatient behavioral health capacity as both state and federal data trends 
confirm (“A Roadmap to Essential…, 2017; “Mental Health Association of Maryland,” 
2015; Sisti, Sinclair, and Sharfstein, 2018). The lack of access and availability of 
treatment providers poses challenges in providing immediate support to patients that 




the top response was to make more investments in behavioral health and crisis 
services. Other barriers included the lack of community resources to assist the social 
needs of patients, including housing, transportation, and prescription drug affordability. 
This study went further than to merely validate other research and studies on the 
effectiveness of a peer recovery specialist role. The study adds new evidence to the 
literature in thinking about the successful implementation science of integrating peers 
into the emergency department, or other hospital environments. Key considerations for 
replicating the program include a commitment to hire and oversee a peer recovery 
specialist team and provide them with dedicated tools and space to work within the 
department. It is also advised that the integration of peers connect directly to other 
providers by documenting within a shared electronic medical record (EMR). Providers 
note that it’s essential to develop strong referral processes through the EMR. 
Strengths and Limitations 
 While a total of 11 interviews were collected for this analysis, only two interviews 
were conducted with OSOP peer recovery specialists. This provided for a more limited 
insight from peer recovery specialists that deliver the program, which in part was due to 
a small number of participants to recruit from within the study setting hospitals. 
However, one of the peers interviewed has served as an OSOP peer recovery specialist 
since the inception of the program at one of the study setting hospitals. This OSOP peer 
recovery specialist has worked with nearly 1,000 opioid overdose survivors through 
OSOP, allowing for substantial insights to be gained. The process to recruit OSOP peer 
recovery specialists may be viewed as a selection bias, as it was not conducted 




workforce (Sherman, 2017). The similarity of the questions asked for all roles – peers, 
physicians, and nurses – allow for emerging themes, however, to be produced from all 
participants.  
 As mentioned earlier, OSOP at each of the four study setting hospitals is an 
extension of other peer recovery specialists that also serve emergency department 
patients. While the physicians and nurses were directly asked questions specific to the 
OSOP, some did not necessarily distinguish their responses between the OSOP peer 
recovery specialists versus the other dedicated peers. This discrepancy was first 
observed when transcribing the interviews when respondents would specifically mention 
peer recovery specialists by name that were not peers dedicated to OSOP. On the 
surface, this phenomenon may appear to be a limitation in the program’s evaluation. 
However, it is believed that the answers provided for the analysis and results of this 
research are defensible. This conclusion is determined because OSOP is a mere 
extension of the other peer recovery specialists working in the study setting hospitals. 
Non-OSOP peer recovery specialists work collaboratively with nurses and physicians to 
refer patients to the OSOP peer recovery specialist. The pool of peers in the emergency 
department is viewed as a collective team by physicians and nurses to effectively serve 
patients with a broad range of substance use disorders, including opioid overdose 
survivors. Thus, the observations from nurses and physicians in working with peer 
recovery specialists serve as defensible contributions to this research, as well as the 
body of peer recovery specialist evaluation literature.  
These findings provide data to hospital administrators seeking value, including 




buy-in from the entire team before launching such a program. This buy-in is suggested 
to be facilitated through solid staff training that conveys role definition and delineation of 
peers. The results also provide specific resources needed to adopt the program, 
including the ability to hire and oversee staff, as wells as workflows, technology, and 
protocols needed for success. These findings bring concrete practice implications in 
assisting with the broader adoption of the program in hospitals throughout the state and 
country.  
Conclusion 
This result of this study suggests that providers and nurses that work alongside 
OSOP peer recovery specialists in the emergency department have positive 
experiences with nearly unanimous observations that these specialists enhance their 
clinical practice and better serve patients. The research confirms that a peer recovery 
specialist’s lived experiences are thought to be the driving force in their effectiveness in 
getting patients to engage while also reducing subsequent hospitalizations. Peer 
recovery specialists know the treatment ecosystem well and use this knowledge to 
advocate to serve their patients. Opportunities for policy and practice changes include 
the need to expand outpatient behavioral health capacity, according to the key 
informants interviewed for this study. Their reflections on the successful adoption and 
integration of the peer recovery specialists and this program can provide insights for 
other healthcare entities (e.g. hospitals, federally qualified health centers (FQHCs), etc.) 
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Figure 1 – Key Informant Guide and Interview Questions for Opioid Survivor Peer 
Recovery Specialists and Emergency Department Physicians and Nurses  
Survey Guide – Opioid Survivor Outreach Peer Recovery Specialists 
Instructions for Student Surveyors. 
The following information should be read verbatim to the participant at the time of 
administering the survey: 
You [participant] are being given the opportunity to participate in a research study 
conducted through Johns Hopkins Bloomberg School of Public Health and the MedStar 
Health Research Institute. Your participation is completely voluntary. This research 
study was developed to better understand the important role and functions of the peer 
recovery specialist serving in the Opioid Survivor Outreach Program. There is no known 
risk to completing the survey and your participation is completely voluntary. Your 
participation, including your responses, will be anonymous. This interview will a 
discussion and conversation that reviews effective strategies to engage patients in the 
OSOP program, best practices, and barriers. You may skip questions that you do not 
wish to answer, and at any time, you can end the interview. The recording is necessary 
to ensure we have accurately captured your response to each question and will be used 
to create a transcription of those responses. After transcription, the recording will be 
permanently deleted and will not be shared to anyone other than the person 
administering the interview. If you do not want to participate, we thank you for your time 
and your choice not to participate in the survey. Your decision not to participate will 




not be shared with supervisors and decision will not affect employment. Your responses 
will not be shared with supervisors or anyone else in the organization of your 
employment. Completion of this survey represents your acceptance of these conditions 
of participation.  
Should you have any questions regarding your participation, please contact Ryan 
Moran at 304-276-8941. MedStar Health Research Institute and Johns Hopkins 
Bloomberg School of Public Health Institutional Review Boards (IRB) have approved the 
evaluation method for this project. If you have any questions or concerns, you may 
contact the IRB. 
May I begin the recording? 
To the Participant: Please state your role and acknowledge whether you are a formally 
certified peer recovery specialist. Please also state how long you have been in this 
position.   
Introductory Discussion 
o Tell me about your role as the Opioid Survivor Outreach Program peer recovery 
specialist. I am interested in what your responsibilities are and what you do on a 
day-to-day basis.  
o Do you feel as though your role has changed from when you first began as an 
OSOP peer recovery specialist? What have you learned since you have started 
that has made you a better peer recovery specialist? 
I. Effective Strategies Used to Engage Patients 
o In your view, what are the most effective ways that you have found to engage 




o Do you find that it is generally easy or hard to get patients to participate? What 
makes it easier for you to get them to participate? 
o For patients that do not enroll in the OSOP program, what have you found to be 
the reasons that they decline to participate? 
o Do you feel the training that you received to become a peer recovery specialist 
was adequate for you to prepare for the role? 
II. Best Practices in Referring and Linking Patient to Substance Use Treatment 
o What barriers have you encountered to referring and linking patients to 
substance use treatment? 
o How important is it for you that your patients get linked to treatment? 
o Describe how you interact with treatment providers in the community. 
▪ What are the most effective ways that you work with these community-
based providers to link patients to substance use services? 
▪ What are the least effective ways to work with these providers in your 
opinion? 
o Describe what support MedStar could provide that would help you to more 
effectively serve patients with substance use needs. 
I want to let you know about some preliminary results of an evaluation of the Opioid 
Survivor Outreach Program and get your reaction to them. We found that by connecting 
patients with an Opioid Survivor Outreach Program peer recovery specialist such as 
yourself, there was a 28% reduction in opioid-related hospital visits over a 12-month 
period and a $440,000 savings to the health system.  




o Were the results as you expected? 
o What do you think it is about the Opioid Survivor Outreach Program that helps to 
reduce patients’ opioid related medical visits? What more could be done to be 
even more effective? 
III. Relationship with Healthcare System as Member of Healthcare Workforce 
o Can you describe your relationship with the physicians, nurses, and other clinical 
providers in the emergency department?  
o What type of communication do you have with these folks? How often do you 
interact with them?  
o What works well and not so well in terms of how your job fits into the emergency 
department?  
▪ How have these relationships with physicians, nurses, and other clinicians 
changed from when you first started as a peer recovery specialist, if at all? 
o Tell me about how you assist and advocate for the patient in the OSOP to get 
connected to substance use treatment or other recovery support services. 
Survey Guide – Emergency Department Physicians and Nurses  
Instructions for Student Surveyors. 
The following information should be read verbatim to the participant at the time of 
administering the survey: 
You [participant] are being given the opportunity to participate in a research study 
conducted through Johns Hopkins Bloomberg School of Public Health and the MedStar 
Health Research Institute. Your participation is completely voluntary. This research 




recovery specialist serving in the Opioid Survivor Outreach Program. There is no known 
risk to completing the survey and your participation is completely voluntary. Your 
participation, including your responses, will be anonymous. This interview will a 
discussion and conversation that reviews effective strategies to engage patients in the 
OSOP program, best practices, and barriers. The recording is necessary to ensure we 
have accurately captured your response to each question and will be used to create a 
transcription of those responses. After transcription, the recording will be permanently 
deleted and will not be shared to anyone other than the person administering the 
interview. If you do not want to participate, we thank you for your time and your choice 
not to participate in the survey. Your decision not to participate will have no effect on 
your role within MedStar Health. Completion of this survey represents your acceptance 
of these conditions of participation.  
Should have any questions regarding your participation, please contact Ryan Moran at 
304-276-8941. MedStar Health Research Institute and Johns Hopkins Bloomberg 
School of Public Health Institutional Review Boards (IRB) have approved the evaluation 
method for this project. If you have any questions or concerns, you may contact the 
IRB. 
May I begin the recording? 
To the Participant: Please state your role and how long you have been in this position 





o Tell me about your overall experience in working with the Opioid Survivor 
Outreach Program and the peer recovery specialist(s) assigned to work with 
Opioid Overdose Survivor patients.  
o How does the OSOP peer recovery specialist relate to you and your job in the 
emergency department? Tell me how you interact with them in your day to day 
practice as a nurse or physician.  
I. Effective Strategies Used to Engage Patients 
o In your view, what are the most effective ways that you have found to engage 
patients to participate in the OSOP program? 
o For patients that do not enroll in the OSOP program, what have you found to be 
the reasons that they decline to participate? 
o In what ways does the OSOP program enhance or detract from your clinical 
practice? Are there things about the way the OSOP operates that make it easier 
or harder for you to utilize their services with your patients? 
o Without the OSOP program, how else would this patient population be served in 
terms of their opioid use disorder? 
II. Best Practices in Referring and Linking Patient to Substance Use Treatment 
o What has been your experience with the peer recovery specialists connecting 
your patients to substance treatment in the community? 
o In your opinion, what are the most effective ways the OSOP peer recovery 
specialists uses to get patients linked to treatment?  
o What barriers do you think the peer specialist has to refer or link patients to 




o Describe what support MedStar could provide that would help you to more 
effectively serve this patient population? (Probes: Could more resources be 
added to support patients with social needs?) 
I want to let you know about some preliminary results of an evaluation of the Opioid 
Survivor Outreach Program and get your reaction to them. We found that by connecting 
patients with an Opioid Survivor Outreach Program peer recovery specialist, there was 
a 28% reduction in opioid-related hospital visits over a 12-month period and a $440,000 
savings to the health system.  
o What is your initial reaction to seeing the data?  
o Were the results as you expected? 
o What do you think it is about the Opioid Survivor Outreach Program that helps to 
reduce patients’ opioid related medical visits? What more could be done to be 
even more effective? 
III. Relationship with Healthcare System as Member of Healthcare Workforce 
o How has your relationship changed with the OSOP peer recovery specialists 
from when the OSOP program first started, if at all?  
o Tell me about ways that you have seen them advocate for patients to receive 
substance use treatment or support services with you or community treatment 
providers. 
o What should other health care systems know about the OSOP program and 





o What type of resources and infrastructure are needed? What are some selling 
points of the program?  
o What are some pitfalls to avoid and how can they be avoided? 
o Is there anything else that you’d like to share regarding the OSOP peer recovery 





























Figure 3: Codebook of Analyzed Results 
Qualitative Results –Codebook 
Providers: Overall Experience Working with Peers 























10 Provider: And then 
as a resource 
nurse, it's kind of 
nice to have that 
extra person there 
to kind of look into 
things and maybe 
even offer a 
dif ferent 
perspective on our 
patients. So, it's 
been a good 
experience to 












with peers to 
connect patients 
to treatment 
5 Provider: I don’t 
even know all the 
resources in 
community because 
our coaches are so 
good with coming 
up with a plan to 
serve patient needs 
with us. 







I. All: Effective Strategies for OSOP / Peer Engagement 









Be Present (2) 
 
Outf it (2) 
Peers are noted 
as being able to 
relate to patients 
because of their 
lived substance 
use experience 
in a way other 
provider cannot 
relate. 
15 Provider: We like 
to reiterate that 
these are people 
[OSOP peer 
recovery 
specialists] that are 
their peers, that 
have been where 
they have 
been…It's easy for 
us as hospital staff 







without us ever 
being in their 
shoes, being where 
they are…We just 
like to relate those 
two things together 
to make the 
individuals more 
susceptible to 









peer early in the 
patient’s care to 
engage them in 
OSOP program. 
6 Provider: They 
of ten get to patients 
very quickly. This 
helps us get a plan 
together to serve 
patients. They 
update us and 
come back.  
Patient 
willingness/readiness 
 Refers to OSOP 
peers 
encountering 




Contact information  Leaving contact 
information 
behind if patient 
is not ready to 
enroll so that 









EMR System  EMR system is 







Fentanyl Test Strips  Providing harm 











Code Sub-Code(s) Code Memo Frequency of 
Observation 
Notable Quotes 
from Participants  
Patient Readiness   Patient readiness 





10 Peer: When they 
are ready, it’s 
easy. If  they are 
not ready, it’s hard. 
Once again, you're 
talking about the 
disease of 
addiction, and a lot 
of  times people 
don't know that 
they have a 
disease. They are 
in denial. When 
you are denial, you 
don't know that you 
are in denial until 
you come out of 
denial. I 
understand the 
process. I’m a 
person myself in 
long-term 
recovery, so I 
understand the 
process. It is easy 
when they're 
ready, and it's very 











Already Engaged in 
Treatment 
 Patient is already 





 Patient resists 
treatment option 





Belief    Patient’s own 




Shame  Patient feels guilty 
for substance use 
issue. 
1  








pressure f rom 
family member to 
enter treatment. 
Seasonal   Changes in 
temperature 
impact participant 





Providers: Enhance or Detract Clinical Practice 
 










peers make it 
easier for their 
practice. 
6 Provider: It clearly 
doesn't detract 
[f rom our clinical 
practice] at all. 
Ever. Clearly, it's 
just as if  it was 
another service that 
we feel we never 
thought about, but 
also now, I can’t 
imagine how we 







ability to do quick 
touches with the 
patient is definitely 
a benef it to our 
practice. 






peers make it no 




Providers: Service to Patient Population Prior to OSOP 
 













that only a list of 
places were 
provided to 
patient in the 









that no services 










return to ED at 
high f requency 






 Hospitals would 








II. All: Best Practices for Linking and Referring Patients to Care 



















behalf  of patients 
to get into care. 
13 Provider: I think 
that a lot of the 
peer recovery 
coaches have ins 
or ties to certain 
place. So, I think 
that they are much 
more ef fective of 
getting people to 
these facilities than 
I might be, or even 
knowing what all of 
them are. Unless 
we do our own 
digging or research 
I just feel like, they 
know much more 




process than we do 
and what the 
patient needs to get 








Refers to the 
amount of time 
peers have to 
devote to patients 
that clinical 
providers do not. 
6  











Advocacy  Assist in order 
placement (2) 











All: Barriers to Refer and Link and Refer Patients to Treatment 
 
 













because of lack 
of  behavioral 
health capacity 
and/or insurance 
issues to accept 
patient. 
13 Provider: I'm 
guessing there's 
probably a limited 
number of places 
they can go for 
recovery and so 
they have a limited 
number of beds and 
staf f to care for 
these patients. 
That’s probably the 
biggest barrier 
having enough 
centers or detox 
centers for the 
patients. 
 
Peer: Some places 
just won't accept it 
[patient’s 





Medicaid. There are 
only two providers 
that take Medicaid, 
or maybe one. If 
they don’t have the 
supplement of A or 
B, then it’s a 
struggle. And then, 
with no insurance, 
we advocate with 
the social work 
team to get them 
some insurance so 
we can get them in 
the door. 




engage in a 
program. 
3  
Geography  Treatment 
options aren’t at 
a convenient 
location for 
patient / their 
family 
2  
Stigma  Patients present 















Peers: Importance of Patients Getting Connected to Treatment 
 
Code Sub-Code(s) Code Memo Frequency of 
Observation 
Notable Quotes 
from Participants  
Important – Very 
important 
 Peers rate their 
importance of 
getting patients 
in treatment as 
important or very 
important. 
2 Peer: Very. That's 
right at the top of 
the list. Top of the 
list. It’s urgent. It’s 
urgent. 
 
Peer: I want to say 
a seven out of ten, 
because yes, I want 
to see them get 




them turn things 
around, but 
sometimes it’s 
going to take three 
months before 
they're willing to do 
that. Yeah, it's 
about the 
relationship that you 
make. I’m not super 
depressed if they 
don’t get sent right 
f rom the ER. It 
upsets me, but 
there’s still more 
opportunities. I don’t 
see it as a failure 
because now I'm 
still going to be in 
contact with them. 
 
 
All: Opportunities for More Support to Patient Population 
 
Code Sub-Code(s) Code Memo Frequency of 
Observation 
Notable Quotes 







in outpatient and 
inpatient 
settings are 
needed to serve 
population. 
6 Peer: The biggest 
by far is availability 
for our area. 




more options is 
needed in order 
to assist them in 
their treatment 
plan. 
2 Provider: I don’t 
know how we could 
provide this, but 
stable housing. 
And if  there's some 
way to assist in 
that regard…Stable 
housing is in the 




 Participants note 
that peers 









Narcan (1) Addressing 









 Of fering de-
escalation or 
stigma language 




Expand Peer Hours  More hours for 
peers are 





All: Initial Reaction to Seeing Patient Utilization and Cost Data  
 










and cost data 
results. 
8 Peer: Well, you 
can't see me, but I 
am shouting. Oh, 
that is amazing. Oh 
my God. My heart 
is so f luttered. YES! 
YES! That's why I 
do what I do, but I, I 
mean, it says in the 
numbers. I'm like 
really built up right 
now, because 
sometimes doing 
his job, you feel like 
you’re not getting 
through. Then to 
hear that it makes 
me know, like, 
okay, right, right, 
yeah, yeah. I work 
really hard. I don’t 
do it, I mean, of 
course, I want a 
paycheck. I do this 
because I truly 
believe this is what 
I was meant to do. I 
do this because I 
believe this is my 
purpose. I do.” 










and cost data. 
 
All: Results Expectation 
 




Less Than Expected  Participants 
respond that 
they thought that 
utilization and 
cost results 












As-Expected  Participants 
respond that 
they thought 





III. All: Relationship as Member of Healthcare Team Relationship Change Since First 
Launched  
 




More Integrated – 
Collaborative 
 Participants 
observe a more 
integrated and 
collaborative 
model since first 
adoption. 
8 Provider: I think 
we engage with 
them so much that 
they are part of our 
department. We 
























patients re: their 
substance use 
disorder 




f irst began. 
1  
No change  Participants 
saying that 




No comment  Participants 
noting that they 
aren’t able to 




Providers: Resources Needed for Success / Considerations for Other Health System Adoption 
 




Peers  Peers are 
needed to 




Of f ice Space  Peers and other 
staf f need space 




Screening Tool EMR (2) Workf low and 
processes must 




Staf f Buy-In  Key to success 
is having buy-in 
f rom all staff that 
work with peers. 
2  
MAT   Providers note 
that it is helpful 
to have initiation 















ef fectively serve 
patients. 
Training – staf f  Program must 










Providers: Selling Points  
 






Program is at 
the heart of  
service in a 
health system 
and aligns with 
hospitals 





 Program helps 
reduce patient 















3 Provider: Others 
should know how 
they can be so 
ef fective in getting 
people linked to 
community 
treatment through 









Staf f Buy-in  Participants note 
that it is crucial 
to have buy in 
f rom staff when 
starting the 
program to 
ensure success.  
5 Provider: Explain 
to your staff what 
the peer recovery 
coach can provide 
and how they can 
help you is huge. 
Because 
sometimes the 
nurses or doctors 
may feel like it is a 
burden. Make sure 
that when you 
integrate the 





to the peer, what 
their purpose is 
and what they are 
there for. You want 
to make sure that 
relationship is well 




was distrust on the 
staf f at the 
beginning. We 
wondered who they 
were and if  they 
would really find 
the resources for 
our patients. But 
watching them do 
it, having rapport 
with the patients 
and understand 
their role has 
changed staff 
perception. 
Weak EMR Referral 
Process (2) 
Workf low and 
processes must 








ef fectively serve 
patients. 
2  





Hours of Peer  Participants note 











Policy Memorandum: Practice and Policy Considerations from Research 
The implications of the results of this research allows for the consideration of four 
distinct practice and policy changes. The first two areas address the opportunity for 
policy and practice implications within the field of state and federal public health, 
including:  
Practice Implications:  
▪ Adoption of Peer Recovery Specialists Program in Other Hospitals 
▪ Expansion of Peer Recovery Specialists in Alignment with Value-Based 
Payment Models 
Policy Implications: 
▪ Provides Evidence for Reimbursement of Peers in Maryland and Broader 
Reimbursement Strategies for Commercial Payors 
▪ Provides Evidence of the Need to Expand the Adoption of Outpatient 
Treatment Options (e.g. MAT) 
Adoption of OSOP or Peer Programs in Other Hospitals  
 One of the purposes of this research was to build on a growing field of evidence 
that peer recovery specialist interventions are not only effective in curbing opioid-related 
deaths but that the integration of these services in hospital settings could prove 
beneficial and in alignment with health system financial incentives. In other words, this 
research sought to examine what would allow more hospital administrators or hospital 
providers to consider the broad adoption of peer recovery specialist services within 
hospitals, specifically emergency department environments. Since the inception of the 




– lowering healthcare cost, improving quality outcomes, and improving patient 
experience – through a variety of incentive programs outlined by CMS policies (Berwick, 
Nolan, & Whittington, 2008).  
Examples of these programs include a focus on reducing hospital readmissions 
through the Hospital Readmissions Reeducation Program (HRRP), as well as the 
Hospital Quality Reporting Program (HQRP). HRRP focuses on the reduction of hospital 
admissions over a 30-day time period for specific chronic diseases such as heart failure 
or chronic obstructive pulmonary disease (COPD) while the HQRP program focuses on 
reducing all-cause hospital visits. Both programs are designed to reduce acute care 
spending while encouraging hospitals to promote sound care coordination practices 
post-hospitalization to improve the patient experience and quality outcomes. Based on 
performance as benchmarked by other hospital peers, CMS rewards hospitals for 
favorable readmission performance or can decrease payment unfavorable performance 
(“Hospital Readmission Reduction,” 2020). This program is applicable for the entire 
country except for Maryland, the setting of the hospitals included in this study. Maryland 
has a unique payment system that entails an agreement with CMS entitled Total Cost of 
Care.  In this arrangement, Maryland hospitals are also incentivized to focus on hospital 
readmissions and are rewarded or penalized like other hospital peers across the 
country (“Maryland All-Payer Model,” 2020). The focus of this research was to make the 
case that the OSOP intervention assists in reducing hospital visits even when compared 
to patients that did not receive such intervention. Further, this research also examined 





The first research aim was designed to evaluate patient utilization over a 12-
month pre and post-period to determine the observed frequency of emergency 
department, observation, and inpatient hospital visits. The results showed a statistically 
significant reduction, in expected opioid-related hospital visits by more than 30% when 
analyzing the pre and post-enrollment periods of the study group. There was an 
observed reduction in expected opioid-related visits between the historical control and 
study groups.  All-cause hospital visits between the two groups did, however, show a 
statistically significant reduction by nearly 39%. These results were as hypothesized 
and provide the foundation for the evaluation of the second research aim, which was to 
examine the value of cost avoidance savings to the health system. Among the four 
study setting hospitals, the net value in cost avoidance as it pertains to hospital charges 
demonstrated favorable and compelling results. Further, the study setting hospitals 
were in urban and suburban areas, which assist in making these findings generalizable 
to other hospitals across Maryland, as well as the rest of the country. The findings from 
a utilization and cost perspective strengthen the arguments to hospital administrators to 
support necessary investments in adopting the OSOP intervention. They also align with 
CMS and state policy goals to reduce hospital readmissions. 
In addition to the results of this study demonstrating financial benefit for 
healthcare institutions to more broadly adopt OSOP, this specific intervention can play a 
role in providing a concrete strategy to address the opioid epidemic based on individual 
hospital community health needs assessments. In a recent review of community health 
needs assessments and implementation strategies of 140 hospitals in 25 states, 70% of 




study also showed that most were addressing how to expand capacity for treatment 
modalities to address opioid use disorder. They also concluded that additional 
incentives were needed for hospital leadership to invest in programs that moved beyond 
addressing opioid use disorder through a medical lens (Singh, Kiessling, & Rhodes, 
2020). The implications of this research provide more incentive for hospitals to invest in 
addressing the opioid epidemic by adopting OSOP as part of their community health 
needs assessment implementation strategy and community benefit reporting.  
 The research provides evidence that may attract hospital senior leadership to 
make the necessary investments from hospital operational budgets rather than 
philanthropic or grant support. However, the results from the in-depth interviews 
conducted provide an array of advice at the hospital-unit level when considering the 
adoption and implementation of a successful OSOP program. As it relates to resources 
needed to operate the program, participants noted the following considerations:  
▪ Adequate peer recovery specialist staffing based on the prevalence of substance 
use in specific communities, as well as proper training that coincides with peer 
recovery specialist state standards. 
▪ Integrated screening tool in the electronic medical record (EMR). This research is 
predicated on the use of Screening, Brief Intervention, and Referral to Treatment 
Model (Appendix: Figure 1). The screening questions used include evidence-
based tools to screen for alcohol and substance use through the Alcohol Use 
Disorders Identification Test (AUDIT) and Drug Abuse Screening Test (DAST), 




▪ Educating all staff at the hospital/unit level to obtain buy-in from the healthcare 
multidisciplinary team as peer recovery specialists are integrated into the 
department. Multiple interviewees suggested that hosting a staff session for peer 
recovery specialists to share about their past substance use experiences, as well 
as the scope of their role is considered best practice to assist with this buy-in. 
▪ Operational logistics such as appropriate staff overseeing peers and dedicated 
office space/area within the hospital department. 
Related to incorporating an OSOP peer recovery specialist as part of an 
integrated multi-disciplinary health care team, interview participants also provided 
insight on pitfalls to avoid:  
▪ Ensure non-peer recovery specialist staff is educated and well-trained on 
screening tools, (especially if integrated into the EMR), referral processes to 
engage peer recovery specialists, and scope of practice of peer recovery 
specialists. 
▪ Foster strong communication practices between peer recovery specialists and 
providers (nurses, physicians, social work, etc.). This communication ensures 
that patient needs are addressed and met.  
Thus, this research provides evidence, data, and shared learnings for a broader 
adoption of OSOP in other hospital environments not only in Maryland, but across the 
country, through the following considerations:  
▪ Proves the efficacy for hospital leadership to implement the program by 
aligning with financial goals and payment policy programs set forth by 




▪ Provides a concrete strategy for hospitals to invest in as part of their 
community health needs assessment strategies and community benefit 
reporting 
▪ Recommends specific workflows, resources, and best practices for other 
hospitals to consider when launching their program. 
Expansion of Recovery Based Peers Align with Value-Based Payment Models 
As mentioned earlier, Maryland’s payment model includes a unique arrangement 
with CMS. Since the 1970s, Maryland has a state-run commission that sets hospital 
rates. This arrangement means that individual health systems and hospitals do not 
negotiate rates with individual payors. In 2014, the state negotiated an agreement with 
CMS to transition to a statewide global budget revenue system, which capped the 
annual revenue for hospitals to control expenditures while also incentivizing quality 
improvement. In the global budget revenue’s second iteration that began in 2019, 
Maryland’s Total Cost of Care program elevates incentives to reduce overall per capita 
spending, improve quality, reduce hospital-acquired conditions, and focus on rooting out 
spending through initiatives that reduce readmissions and potentially avoidable 
utilization (“Maryland All-Payer Model,” 2020). Maryland’s measurement of potentially 
avoidable utilization “hospital care that is unplanned and can be prevented through 
improved care, care coordination, or effective community-based care or care cost 
increases that result from a potentially preventable complication occurring in a hospital” 
(“Health Services Cost Review Commission,” 2014). Germane to this study, as part of 
the Total Cost of Care model, it encourages hospitals to focus on population health 




both mental health and substance use, diabetes, and care for older, medically complex 
older adults (“Maryland’s Total Cost of Care Model,” 2017). Paired with other care 
transformation initiatives and quality-based reimbursement incentives, the selection of 
the three population health areas occurred based on the opportunity of improving health 
for the state, decreasing mortality, and decreasing aggregate acute care spending. 
Through these initiatives, by the end of 2023, the state has agreed to reduce Medicare 
overall spend by $300 million annually through the combination of all initiatives 
(“Maryland’s Total Cost of Care Model,” 2017). 
However, while the state put forth behavioral health services with an emphasis 
on hospitals to address the opioid epidemic as a component of the Total Cost of Care 
Model, policymakers proposed limited statewide strategies or roadmap for hospitals to 
implement. In fact, in the agreement with CMS, Maryland is to set forth goals in each 
area in 2020. These goals cemented have been delayed by the state’s focus on 
combating the COVID-19 global pandemic. The state agency responsible for the 
formation of a statewide plan is the Maryland Opioid Operational Command Center, 
formed by Governor Larry Hogan after the state of emergency was declared in 2017 
(“Maryland’s Total Cost of Care Model,” 2020). Data and previous studies conducted by 
the Maryland Hospital Association demonstrates the opportunity to address behavioral 
health readmissions. A review of patients in 2016 statewide found that patients with a 
behavioral health diagnosis, which could be inclusive of a substance use-related visit, 
had a readmission rate of 15% while all other non-behavioral health diagnosis patients 
had a readmission rate of 11% (“A Roadmap to an Essential,” 2017). The premise of 




the Opioid Survivor Outreach Program, could not only be an invaluable tool to save lives 
from the opioid epidemic but could be a means to include as part of value-based 
programs. The study setting of this research, namely their location in the state of 
Maryland, provided for an appropriate review of this question. 
In the formation of population health metrics for Maryland’s Total Cost of Care 
Model, this research provides solid evidence for the inclusion of impact measures 
produced by the Opioid Survivor Outreach Program. This study suggests that a broader 
analysis of the implementation of this program across the state’s hospitals would align 
with the primary goal of the state’s model to reduce overall acute care spending. In the 
study setting of four hospitals in Maryland, the research suggests that OSOP allows 
healthcare systems to avoid an estimated $773,323 in hospital charges. The study 
setting also includes urban and suburban hospitals, as well as a study population that 
demographically reflects statewide opioid-related deaths in the state from previous 
years. Both points assist in making the study findings on cost avoidance generalizable 
to other hospitals in the state. Further, the four study setting hospitals included in this 
research were among the earlier adopters of the program. According to the Mosaic 
Group, the consultant agency working closely with the Maryland Department of Health 
to implement OSOP, the program is now operational in 28 hospitals across the state 
(Oros, 2020). It is hypothesized that a broader and more long-term review of patient 
utilization and associated cost data would yield an even more significant amount of 
acute care spending. 
There is one limitation in the effort to integrate OSOP impact measures as part of 




and rooting out Medicare annual spending; however, a majority of those in the study 
population of this research were enrolled in Medicaid. However, based on reviewing 
data of previous years of opioid-related deaths in the state, one would expect most 
patients enrolling in the program to be more likely recipients of Medicaid than Medicare. 
This is based on the requirement to be at least 65 to be eligible for Medicare. Of all 
opioid-related deaths in Maryland in 2018, 75% of individuals were under the age of 55 
(“Opioid Overdose Deaths,” 2020). Based on the metric selected, the Maryland 
Department of Health should, in the evaluation of Maryland’s Total Cost of Care Model, 
include Medicaid spending. Regardless of the payor type, this research further 
confirmed evidence that opioid-related hospital visits are associated with higher 
charges, and therefore, cost, when compared to non-opioid-related hospital visits. Data 
from this research also showed that OSOP was not only effective when evaluating 
aggregate acute care hospital charges. Data also showed that patients enrolled in 
OSOP and experienced an opioid-related hospital visit observed significantly fewer 
hospital charges when compared to patients not enrolled in the program. The difference 
in chargers per visit in the post-period was nearly $900. 
In summary, this study provides a foundation of evidence that the peer recovery 
specialist intervention aligns with value-based payment models. The results offer the 
following concrete practice and policy changes:  
I. OSOP as an intervention aligns with Maryland’s Total Cost of Care 
Program and the below impact measures should be included as part of 
the state’s population health program goals:  




•  Value of Cost Avoidance from an Acute Care Perspective for 
Enrollment in OSOP  
II. Given the opioid epidemic’s impact on a population that primarily is 
enrolled in Medicaid, Maryland should work with CMS to ensure that 
Medicaid cost avoidance savings are accounted for in its effort to 
reduce aggregate acute care expenditures. 
III. Provides evidence for other states, commercial payors, or health 
systems investing in value-based models to consider OSOP as a 
mechanism to reduce cost, improve quality metrics such as mortality, 
and improve patient experience/value. 
Provides Evidence for Reimbursement of Peer Recovery Specialists in Maryland 
and Broader Reimbursement Strategies for Commercial Payors  
 The foundation of this research was to assess not only if peer recovery specialist 
programs such as OSOP could be used as effective ways to respond to the opioid 
epidemic but evaluate its success through the lens of population health metrics – patient 
utilization and cost. When peer recovery specialists engage opioid overdose survivors, 
a vulnerable, high-risk patient population, the results of this research illustrate a 
reduction in subsequent opioid-related hospital visits and a respectable financial value 
of the health system avoiding unnecessary cost. The advent of the role of a peer 
recovery specialist is not new to the field of public health. Their inception in the United 
States dates to the 1970s with an increase of their use in the field most recently by 




 Since that timeframe and as peer recovery specialists have become embedded 
in healthcare delivery settings, states have worked to partner with the Centers for 
Medicaid and Medicare Services (CMS) to seek reimbursement for their services. The 
evolution of peer recovery specialists becoming a reimbursable service through CMS 
started with Georgia in 1999. Fourteen years later, CMS issued formal guidance to 
other states on how they could become eligible for peer services to be reimbursed. 
These requirements include having a formal curriculum training for peers and a state-
run process for formal certification (Videka et. al., 2019). The driver for reimbursement 
has been driven by two industry dynamics. The f irst is that reimbursement provides a 
sustainable funding source for organizations, such as hospitals, community-based 
providers, and treatment centers, to hire peer recovery specialists. The other dynamic 
relates to the results of this research. Recent studies have demonstrated that peer 
recovery specialists generate savings for members in health insurance plans. For 
example, Bouchery et. al. (2018) found that crisis centers that had peers as part of their 
service model resulted in approximately $2,138 savings per Medicaid enrollee when 
compared to treatment centers not staffed with peers. A separate study evaluating the 
use of peers in Georgia showed a cost savings of  nearly twice that amount for 
individuals receiving behavioral health care (Videka et. al., 2019).  
However, even with the evidence provided by studies predating this research, 
reimbursement of peer recovery specialist services has not been universal nor is there a 
consistent approach between the states where reimbursement is permissible. In a 
recent comprehensive report issued by the University of Michigan Behavioral Health 




peer services to be reimbursed through Medicaid, following Georgia’s first adoption in 
1999. Maryland, the study setting of this research, was one of the states that do not 
allow for reimbursement even though the state has formal standards for training 
curriculum and has developed a state-wide certification program (Videka et. al., 2019). 
The results of this research present a compelling case for reimbursement. 
Maryland’s policymakers have recently taken steps to evaluate the utility and feasibility 
of reimbursing for peer services. In 2018, the Maryland General Assembly based House 
Bill 722 (Senate Bill 765) that required the formation of a workgroup of experts within 
the field to provide a report to legislators and Maryland’s Governor by January 2019 
(“Consumer Affairs – Maryland Department of Behavioral Health Administration,” n.d.). 
No further action has been taken. However, this research solidifies a recommendation 
for Maryland, as well as the eight other remaining states, to pass legislation that would 
allow each state Medicaid program to reimburse for peer recovery specialist services. 
As the results indicated, doing so would allow for the broader expansion of peer 
recovery services to serve state residents while at the same time prevent unnecessary, 
avoidable acute care utilization that generates savings for the healthcare system.  
The University of Michigan’s national review of peer recovery specialist 
reimbursement services also found inconsistent methods on allowable services for 
reimbursement, as well as the mechanisms used to reimburse for services. For 
example, not all states approve reimbursement for peer recovery services that focus on 
substance use disorder. For example, 12 states allowed reimbursement for peer 
services for only mental health conditions. On the other hand, four states only provide 




This is one example of the variability of payment policy practice among states. 
Additionally, a report issued in July 2019 to Congress by the Medicaid and Children’s 
Health Insurance Program (CHIP) Payment and Access Commission showed a great 
disparity in the consistency of approach that states used to reimburse for peer recovery 
services specific to substance use services (Recovery Support Services for 
Medicaid…,” 2019).  
The most common reimbursement mechanisms through Medicaid include the 
state plan rehabilitation option. Through Medicaid payment policy, this option allows for 
reimbursement for peer services if patients are being served only for substance use 
needs. Other most common options were waiver and demonstration programs. The 
most common waiver used is the Section 1115 waiver, which gives states the option to 
implement and test new approaches to care while also reimbursing for these services. 
Another is through demonstration projects that incentivize community behavioral health 
clinics to adopt peer services and providing them reimbursement to help sustain the 
peer services offered to their patients (Recovery Support Services for Medicaid…,” 
2019). The inconsistencies of each state’s approach, nonetheless, do not create a 
standardized platform nor does it necessarily guarantee the reimbursement of peer 
services post-waiver or demonstration programs. Further, the difference in approach 
has created disparity across the country in the specific amount of reimbursement 
allocation for peer recovery specialist services’ time. As reported by Videka et. al., the 
average for 15 minutes of peer recovery specialist services across the country was 




states do not use the same coding structure to formally bill for these services (Videka et. 
al., 2019). 
The other challenge with the variety of payment mechanisms is that some 
approaches in certain states may not extend reimbursement of peer recovery services 
to hospital entities. For example, hospitals providing peer recovery services in states 
where Medicaid only reimburses for peer services through community behavioral health 
clinics would not be eligible for reimbursement. CMS guidelines for peer recovery 
service reimbursement may also be a limitation for hospitals to receive reimbursement. 
Per their reimbursement guidelines, peer recovery specialists must be supervised by a 
mental health professional, including, but limited to social workers, psychiatrists, or 
other psychotherapist professionals (“CMS Guidance…,” 2007). Hospitals that operate 
in rural areas or hospitals that do not have a robust array of behavioral health clinicians 
or service line may not be able to meet these requirements. To ensure the broad 
application of the reimbursement of peer recovery services in a hospital setting as 
dictated by this research, the following policy recommendations include:  
I. Evaluate the array of payment mechanisms currently in place by 41 
states to reimburse for peer recovery specialist services for both mental 
health and substance use disorder services. 
II. Determine a nationwide, universal standard recommendation for 
reimbursement through Medicaid that could be emulated for commercial 
payors to also adopt in their payment policies. 
III. Provide a recommended fee schedule for peer recovery specialist 




schedule could also serve as a recommendation for a commercial payor 
payment policy. 
IV. Ensure new guidelines allow for the reimbursement of a broad range of 
health providers, including hospital-based entities. Other providers 
include but are not limited to inpatient and outpatient mental health and 
substance use disorder facilities, detox facilities, and short and long-
term residential entities. 
Provides Evidence of the Need to Expand the Adoption of Outpatient Treatment 
Options (e.g. MAT) 
 This research evaluated the impact of peer recovery specialist intervention as it 
pertains to avoiding healthcare system costs. The hypothesis in reviewing cost as a 
research aim was to make the case that peer recovery specialist programs can reduce 
acute care spend. It is hypothesized that the reduction in hospital visits may be because 
patients get connected to outpatient treatment settings. This not only connects the 
patient to a long-term treatment program, but outpatient environments are deemed a 
more appropriate, cost-effective setting. The results of this study only include an 
analysis of the savings derived from acute care utilization. Therefore, the analyzed 
results are not reflective of a patient’s total cost of care, inclusive of considering both 
inpatient and outpatient charges. This research did, however, prove and validate 
existing literature related to the costly inpatient care associated with opioid-related 
hospital visits. This study found a statistically significant difference in comparing the 
average charges for opioid-related and non-opioid related hospital visits. These findings 




expenditures, including hospital visit expenditures to be nearly double for patients when 
compared to those that did not use opioids.  
Previous studies, however, have demonstrated the efficacy of outpatient 
treatment options to treat opioid use disorder. One of the most common treatment 
methods for opioid use dependence is medication treatment through the modalities of 
methadone, buprenorphine, and naltrexone. In the context of this research, the OSOP 
peer recovery specialists may refer patients to these treatment options. As previously 
cited in the literature review, these medication treatment options show favorable results 
when examining healthcare costs. In an aggregate review of more than 13,000 patients, 
total healthcare costs were 29% lower for patients that receive one form of these 
medications (Baser, Chalk, Fiellin, & Gastfriend, 2011). Work in Vermont of assessing 
its Medicaid expenditures showed a reduction in hospital visits and healthcare costs for 
nearly 6,000 state beneficiaries for patients utilizing these medications (Mohlman et. al., 
2016). Other research has looked to assess the impact of not only medication therapy, 
but other options such as detoxification facilities, intensive outpatient treatment, and 
other behavioral health outpatient care (e.g. counseling services). SAMHSA also notes 
that patients receiving medication therapies such as buprenorphine or methadone 
benefit from a mixed approach with counseling services and peer recovery support 
(“Medications for Opioid Use Disorder,” 2020). The results in a cohort study 
demonstrated that after a new diagnosis of an opioid-related disorder, those receiving 
these different types of treatment showed decreased costs compared to patients 
receiving no treatment. The only caveat to that finding was that costs increased for 




the researchers encouraged increased outpatient capacity to reign in healthcare costs 
related to opioid use (Larochelle et al., 2020). 
 While the literature dictates that outpatient treatment settings improve patient 
outcomes and reduce overall healthcare spending, this research validates data at the 
state and national level son the lack of behavioral health service capacity. The results 
from the in-depth interviews conducted provide an array of evidence from frontline staff 
that the most significant barrier that the OSOP peer recovery specialists have in getting 
patients linked to treatment is the availability and accessibility of treatment providers. 
Further, when nurses, physicians, and peer recovery specialists were asked in the 
interviews what more could be done to assist the study population, the top answers 
provided were for the health system to develop in-house treatment programs to expand 
such capacity. A list of quotes from participants highlight how the challenges of 
treatment accessibility and availability impede peer recovery specialists from servicing 
patients. 
Provider Quotes: 
▪ “I'm guessing there's probably a limited number of places they can go for 
recovery and so they have a limited number of beds and staff to care for these 
patients. That’s probably the biggest barrier having enough centers or detox 
centers for the patients.” 
▪ “Sometimes they're not able to find a bed, and I don't know if that's because 
there's not enough recovery centers available or they are full at that time. 
Sometimes we do have to board the patients for a couple hours or overnight up 





▪ “The biggest [barrier to link or refer patients to treatment] by far is availability for 
our area. That’s the biggest and pretty much only barrier. When people are ready 
to go [to treatment], it’s frustrating…” 
▪ “Some places just won't accept it [patient’s insurance]. A lot of patients have 
Medicaid. There are only two providers that take Medicaid, or maybe one. If they 
don’t have the supplement of A or B, then it’s a struggle. And then, with no 
insurance, we advocate with the social work team to get them some insurance so 
we can get them in the door.” 
Other analyses where the study hospitals provide acute care services validate 
these findings. In 2016, hospital leaders in partnership with the Maryland Hospital 
Association conducted a review of behavioral health capacity – both in terms of mental 
health and substance use disorder services. Pertaining to inpatient care capacity, all 
facilities were found to be operating at near full capacity, even as emergency 
department visits for behavioral health complaints increased by 20% between 2013 and 
2016. This increase is a correlation to the rising opioid epidemic. Of even more concern, 
the state’s inpatient bed capacity for psychiatric beds decreased by nearly 3,000 beds 
since 1982 (“A Roadmap to an Essential,” 2017).  The reduction of inpatient bed 
capacity, however, has not been set off by the expansion of outpatient, community-
based behavioral health services. At the early advent of Maryland’s health insurance 
exchange, health insurance plans available for the public to enroll had limited 
psychiatrist availability to see new patients (“Mental Health Association of Maryland,” 




behavioral health capacity, specifically for substance use order. On the national level, 
between 1970 and 2014, there has been a significant decline in inpatient psychiatry 
beds, which provide access to acute services for substance use and mental health care. 
The analysis found a 93% reduction in overall psychiatric beds in state-run facilities 
from 1970-2014 (Sisti, Sinclair, and Sharfstein, 2018). 
 The favorable results of the OSOP program contributing to cost avoidance raises 
the question – what if there was more behavioral health capacity locally and nationally 
to serve this patient population? How much of an impact would the expansion of more 
cost-effective outpatient treatment approaches have on further reducing acute care 
expenditures through the implementation of programs such as OSOP? The research 
validates not only the need for the expansion of outpatient substance use treatment 
options but also adds evidence that such expansion is an opportunity for state and 
federal policymakers to reduce healthcare costs. This research, however, was not 
predicated on evaluating, or assessing specific types of treatment options as being the 
most cost-effective in reducing healthcare costs. The results do provide a narrative for 
existing policy recommendations that would expand treatment capacity to be 
accelerated for adoption. 
 In a recent report by the Brookings Institution, Kilmer (2020) provides ten 
comprehensive approaches that would provide for the further expansion of treatment 
access, and therefore, reduce overdose deaths. Relevant to this research, three pieces 
of federal and state legislation that could be advanced to support expanding access to 
opioid treatment services. First, the Affordable Care Act of 2010 ensured coverage of 




access through states that decided to expand Medicaid. As of August 2020, 12 states 
still have not expanded Medicaid as an option (“Status of State Medicaid Expansion,” 
2020). As observed in both the historical control and study groups of this research, a 
majority of those struggling with opioid use disorder were Medicaid enrollees. By states 
continuing to hold out from Medicaid expansion, it limits millions from not being able to 
access necessary care and treatment options. Five of the twelve states – Wisconsin, 
Tennessee, North Carolina, South Carolina, and Flordia – rank in the top half of states 
as it pertains to opioid overdose deaths per 100,000 persons (“National Institute on 
Drug Abuse,” 2019). Expanding Medicaid access would allow more funding to be 
received by healthcare entities and providers to fund peer recovery specialists, making 
these support services more widely accessible to patients across the country.  
 Even though the Affordable Care Act of 2010 also required coverage of mental 
health and substance use services, in Kilmer’s latest report, compliance to cover all 
opioid-related treatment options has not been realized. For example, the primary 
medication treatment modalities for opioid use disorder – methadone, buprenorphine, 
and naltrexone – are not covered by all insurance providers. Methadone is most subject 
to payment policy debate. It is better covered as a benefit under insurance plans to treat 
pain rather than opioid use disorder (Vuolo, Oster, Maxwell, and George, 2019). 
Evidence of all three medications is substantive and compelling to include all three 
modalities as an approach to treating opioid-use disorder, including reducing the risk of 
opioid-related substances such as heroin and fentanyl, as well as a reduction in overall 




 Even though the efficacy of these treatment modalities is well documented, the 
availability to patients to see providers that are equipped to prescribe and provide on-
going care is limited. The primary limitation is that federal guidelines require rigorous 
training for physicians and advanced practice clinicians, such as nurse practitioners and 
physician assistants, to administer buprenorphine. Once training is completed, the 
providers are then limited to the number of patients that they can prescribe and treat at 
any given time. This entire process is facilitated by the United States Drug Enforcement 
Administration (DEA) and is known as the process of becoming “waivered providers.” 
Any provider, however, regardless of specialty can prescribe buprenorphine if they 
follow these federal guidelines. Thus, this clinical oversight is not reserved for only 
behavioral health medicine providers – e.g. psychiatrists. Founded in wanting to ensure 
patient safety and limit the access of the medication for the further prevalence of opioid 
misuse, there is mounting evidence and call for the DEA to reduce its stringent 
application of the waiver program to expand treatment access. Fiscella, Wakeman, and 
Beletsky (2019) advocate on a platform of three premises to deregulate the waiver – (1) 
Buprenorphine has now been proven through substantive research and clinical trials to 
be safe; (2) Decreasing regulation would support a nation in crisis as it responds to the 
opioid epidemic, allowing more providers to be encouraged to prescribe; (3) More 
patients could be seen as providers, especially primary care physicians and advanced 
practice clinicians in internal medicine would serve as treatment access. The latter 
outcome of deregulating the treatment medication in France yielded more providers in 




They outline specific policy changes for adoption, as well as those federal agencies 
responsible for making such changes in the below chart, Figure 1. 
Figure 1: Buprenorphine Policy Roadmap of Aims, Actions, and Accountable 
Entities 
 
(Fiscella, Wakeman, & Beletsky, 2019) 
 This research adds to the evidence in the public health field that there is an 
inadequate treatment infrastructure and capacity to respond to the current opioid 
epidemic. It reveals how historical changes to reduce behavioral health capacity – 
mental health, substance use, and co-occurring conditions – leaves a nation and 
healthcare ecosystem with limited options to address the need appropriately. This 
research indicates that expanding outpatient treatment capacity to serve patients with 
substance use disorder can have a positive impact on reducing acute care utilization 
and financial expenditures. This proves beneficial for several stakeholders – the patient, 




issues, the following points give a summary of immediate, as well as long-term steps 
that localities, states, and federal agencies must take to curb the current, and rising, 
crisis.  
I. Allocate funds through legislative priorities at the state and federal level 
to expand and build new outpatient treatment services, including mental 
health/crisis services, residential treatment programs, and incentives 
for students to become behavioral health medicine providers.  
II. States that have not pursued Medicaid should consider doing so to 
provide access to treatment services to at-risk, vulnerable individuals 
that may not seek appropriate care.  
III. Federal agencies must enforce all insurance providers to cover 
medication treatment modalities – buprenorphine, methadone, and 
naltrexone – equitably to not only treat pain, but opioid-use disorder.  
IV. Federal policymakers and agencies must consider changes to training 
guidelines and prescribing protocols for providers that would make 
buprenorphine more accessible. The traditional waiver process for 
providers to prescribe this medication is outdated and out of alignment 
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Figure 1: Screening, Brief Intervention, and Referral to Treatment Components 
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